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Abstract
The presentation and neurobiology of depression in young adults is an important but under¬
studied area of psychiatric research. Many young adults with early-onset recurrent major
depressive disorder (MDD) have a strong genetic loading for mood disorder and, in the longer
term, may be at high risk of developing bipolar affective disorder (BPAD). The objectives of
this thesis were two-fold: firstly, to assess the prevalence and clinical validity of bipolar
spectrum disorder (BSD) in a consecutive sample of young adults with recurrent depression;
and secondly, to carry out a neurocognitive study comparing clinically recovered (euthymic)
young adults with recurrent MDD, euthymic BSD patients and well-matched controls.
Eighty-seven young adults presenting with recurrent depression were recruited from
consecutive referrals to a psychiatric clinic at a University Health Service. Of these, 14 had
BPAD, 27 had BSD and 46 had recurrent MDD. The classic criteria used to assess the
validity of psychiatric diagnoses (namely, clinical phenomenology, clinical course, family
history and treatment response) were applied to the BSD group of patients. This provided
only modest support for the validity of the BSD criteria according to clinical parameters.
However, on neurocognitive testing, there were significant differences between BSD patients,
MDD patients and controls in terms of performance on tests of attention, executive function
and declarative memory. This finding suggested that the diagnsotic criteria for BSD were
able to identify a sub-group of young adults with recurrent depression and strong bipolar
features (such as a family history of bipolar disorder or a personal history of antidepressant-
associated hypomania) who performed less well than young adults with more straightforward
unipolar depression on tests of prefrontal and hippocampal functioning. The implications of
these findings for the concept of bipolar spectrum disorder, and for our understanding of the
neuropsychology of mood disorders, are discussed. Limitations of this work and directions
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1.1 Depression in young adults
Using the measure of disability-adjusted life years, the Global Burden of Disease
report determined that in 1990 unipolar major depression was the fourth leading cause
of disease burden in the world [1], By 2020, it is estimated that depression will be the
second leading cause of disease burden worldwide [2], Research efforts investigating
the causes and treatment of depression represent a major challenge for psychiatry and
are likely to have considerable implications for public health [3].
The term 'depression' can be understood to describe a heterogeneous
collection of disorders, ranging from mild subthreshold forms such as dysthymia
through to major depressive disorder (MOD) and more severe forms such as bipolar
affective disorder (BPAD). Depressive subtypes can differ in terms of factors such as
age at presentation, gender and psychiatric or medical comorbidity. To date,
depressive disorders with an onset in adolescence or early adulthood have been a
relatively neglected area of mood disorder research. This is despite evidence to
suggest that severe and chronic forms of mood disorder often begin early in life.
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1.1.1 Epidemiology of depression in young adults
Although most epidemiological studies estimate that at least 5% of men and 10% of
women will suffer from depression at some point during their lifetime [4, 5], there is a
relative paucity of studies focusing on populations of adolescents and young adults.
Depressive symptoms appear to be relatively common in early adulthood. A recent
Finnish study of young adults identified a one-month prevalence for major depression
of 10% [6], It also appears to be the case that adolescents with sub-diagnostic levels
of depressive symptoms will have higher subsequent rates of adulthood depression
[7], When symptom severity reaches the threshold for diagnosis in adolescence it is
likely that this depression will recur during adult life [8, 9].
The Maudsley long-term follow-up study of child and adolescent depression,
which followed 149 subjects over 20 years, found that 62.4% experienced a
recurrence of major depression [10]. Rates of suicidal behaviour were also high, with
44.3% attempting suicide at least once during the follow up period [11].
That women are twice as likely as men to suffer from depression is a
consistent finding in psychiatric epidemiology and does not appear to be simply a
consequence of females being more likely to report, recall or seek help for depressive
symptoms. Before puberty, boys are slightly more likely than girls to experience
depression but between the ages of 11 and 13 this trend is reversed, with girls
outnumbering boys by two to one [12]. This predominance of females over males
then persists for the next 35 to 40 years, although the reasons for this are largely
unknown. Pubertal changes in gonadal steroids may be part of the explanation. It has
been suggested that hormonal changes in adolescence, combined with dramatic
changes in social environment, role expectancies and relationships, might stimulate
14
the development of greater affiliative needs in females, such as a preference for
intimacy and emotional responsiveness. One possible result of this is that adolescent
girls may be more vulnerable to the effects of negative life events, especially those
events with interpersonal consequences [13].
In the United Kingdom, suicide is now the commonest cause of death in young
men between the ages of 25 and 34 [14], Epidemiological studies suggest that
although factors such as poor schooling, poverty and unemployment are important,
the strongest risk factors for suicide in this group are a personal history of mental
illness, and a family history of suicide or mental illness [15]. In a psychological
autopsy study of suicide in 27 young people aged between 15 and 24, Houston and
colleagues found that 70.4% suffered from a mental illness and that depression was
the most common diagnosis, affecting 55.6% of those studied [16]. Almost 30% of
these subjects had a diagnosis of personality disorder and one third had another co-
morbid psychiatric disorder.
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1.1.2 Aetiology of depression in young adults
Under a commonly held model, depressive episodes in young adults probably occur
as a consequence of a wide range of environmental risk factors interacting with
genetic predispositions for mood disorder. A large body of research has established
that factors such as a positive family history of mood disorder, childhood adversity,
recent life events and drug and alcohol misuse are important in the aetiology and
pathogenesis of depression.
The role ofgenetics
Over the last 50 years a number of family and twin studies have highlighted the
importance of genetic predisposition in the development of depressive disorders. The
prevalence of depression in the relatives of depressed probands is approximately three
times that in the general population [17] and concordance rates for monozygotic and
dizygotic twins are approximately 40% and 11% respectively (figure 1) [18. 19].
Adoption studies of monozygotic twins reared apart have suggested that most of the
familiality in depression occurs for genetic rather than environmental reasons [20].
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Figure 1. Family and twin studies for major depressive disorder
Despite evidence for the genetic transmission of depression, molecular genetic
approaches have so far been inconclusive. Although a combination of linkage and
association studies have identified a number of candidate genes, such as tyrosine
hydroxylase, catechol-O-methyltransferase, the serotonin transporter, and several
serotonin receptors (including 5HT2c, 5FITla and 5HT2a), none of the findings to
date have been consistently replicated [21].
One explanation for this is that mood disorders are genetically and
phenotypically heterogeneous. Depression probably encompasses several clinical
sub-groups, some of which are likely to be more heritable than others. One such sub¬
group may be recurrent early-onset major depressive disorder (MDD), which has been
defined as two or more episodes of major depression with onset before the age of 22
[22, 23], Recurrent MDD under this definition is associated with a strong family
history of affective disorder (over one third of first degree relatives and one fifth of
extended relatives have a lifetime history of depression) and appears to follow a
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particularly malignant course, with frequent recurrence, poor response to treatment
and high psychiatric and physical morbidity [23, 24],
Childhood adversity
Childhood physical, emotional and sexual abuse are established as important risk
factors for the development of a range of psychiatric disorders in adult life and are
increasingly recognised as important in early-adulthood psychopathology. Traumatic
experiences can interfere with normal emotional and psychological development with
the result that abused or neglected individuals often struggle to negotiate the
maturational tasks of adolescence and early-adulthood [251.
The observation that not all abused individuals develop significant
psychopathology in later life suggests that our susceptibility to stress may be
dependent upon our genetic make-up. To some degree, this has been demonstrated
recently in the Dunedin longitudinal study where it was shown that individuals with
the less transcriptionally active short (S) allele of the promoter region of the serotonin
transporter gene, in contrast to those with the long (L) allele, were more likely to
*
experience an episode of major depression in the context of life events [26]. This
notion of genetic resilience is also supported by recent work on depression in
adolescent girls. The Virginia Twin Study of Adolescent Behavioural Development
was used to assess the effects of independent life events on depression in 1 84 female
twin pairs [27], Here it was found that there was no effect of independent life events
on depression in the absence of a positive history of emotional disorder in parents,
suggesting a gene-environment interaction whereby genetic factors played a
significant role in mediating the effects of stress in this group [27],
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Recent life events
Although it is established that negative life events can precipitate depression, the
association is a complex one and is likely to operate bidirectionally: people with
depression are more likely to generate stressful events, and individuals with a higher
genetic loading for affective disorder are more likely to experience depression after a
stressful event than those with low genetic loading [27, 28],
In recurrent MDD the association between life events and depression is
strongest for early episodes and becomes weaker as the number of episodes increases
[29], Recurrent depressive episodes tend to become more autonomous and are
progressively less linked to environmental adversity, a phenomenon which has been
termed 'kindling' [30], Kindling tends to be most marked in individuals at low-
genetic risk of depression with those with at high genetic risk exhibiting
'prekindling'. Prekindled individuals appear to become depressed after only minimal
environmental provocation [31]. One important implication of this is the possibility
that young people with a strong family history of affective disorder may be
constitutionally vulnerable to the effects of even minor psychosocial stressors.
Substance misuse
Drug and alcohol use in adolescence are important risk factors for the development of
affective disorders in early adulthood and are likely to complicate the long term
course of depression. In a five-year longitudinal study of 155 adolescent females,
Rao and colleagues found that 18.7% developed a substance misuse disorder and that
substance misuse was a marker for the eventual occurrence of depression [32],
Conversely, when 274 previously depressed adolescents were followed to age 24, two
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thirds experienced another depressive episode and. within the remaining third who did
not, 77% were found to have a substance misuse disorder [33],
Cannabis use in the United Kingdom has now reached such a high level that
the majority of young people have tried it at some point [34]. Although an association
between cannabis and psychotic illness (especially schizophrenia) is well recognized,
much less attention has been paid to its association with mood disorder. Evidence is
emerging for an important relationship between cannabis use and depression in young
adults [35]. Although cross-sectional surveys confirm strong correlations between
cannabis and depression [36], they tell us little about the causal mechanisms in
operation. It may be that those who are pre-morbidly depressed are more likely to use
cannabis as a form of self-medication [37], Alternatively, higher use in depressed
groups may be related to confounding factors such as social deprivation, early
adjustment problems and poor academic achievement [38],
Two recent longitudinal studies support the view that regular cannabis use at a
young age is a precursor of depression in early adulthood. In the first, 1601 students
were followed between the ages of 14 and 21 [39]. It was found that daily cannabis
use in adolescence was associated with a significant risk of anxiety and depression in
early adulthood. This was particularly true for teenage girls: those who used cannabis
on a daily basis were 5 times more likely to have depression than non-users [39].
In a similar investigation, the New York State Children in the Community
Study, a cohort of 736 children were followed between the ages of 14 and 27 [40],
Here it was found that regular cannabis use was strongly predictive of depression as a
young adult. Furthermore, those who began to use cannabis in their early teens were
at higher risk than those who began in their early twenties, suggesting that a critical
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period might exist during which the brain is particularly sensitive to the neurotoxic
effects of cannabis.
There is also considerable co-morbidity between alcohol use and depression in
young adults [411. That alcohol use at a young age is associated with a higher risk of
depression in young adulthood is also supported by the New York State Children in
the Community Study. Earlier alcohol use significantly predicted not only depression
but also any substance use disorder and alcohol dependence by age 27 [40],
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1.1.3 Pathophysiology of depression
In recent years the classical monoamine theory of depression, although still relevant,
has matured into a molecular and cellular theory, which suggests that overactivity of
the hypothalamic-pituitary-adrenal (HPA) axis (Cortisol hypersecretion) is central to
the pathophysiology of depression [17, 42], Traditionally, HPA overactivity has been
demonstrated in severely depressed patients by non-suppression of morning Cortisol in
the dexamethansone suppression test (DST). However, this test did not prove to be an
abnormality that was specific to mood disorders - dexamethasone non-suppression
was subsequently identified in a number of other psychiatric disorders, including
schizophrenia and dementia. A more recent modification of the DST, the combined
dexamethasone/CRH (corticotrophin releasing hormone) test, has been shown to be
more specific to depression [43] and is also exaggerated in the clinically-well first
degree relatives of depressed probands [44, 45],
It is uncertain how this hyperactivity of the HPA axis arises. It may be a
consequence of severe early life stress. For example, Goodyer and colleagues have
found that suboptimal care during the first six months of life is associated with higher
morning Cortisol in adolescence and higher risk for subsequent psychopathology [46].
HPA activity may also arise from a strong genetic loading for affective disorder [47].
Recent work suggests that high levels of corticosteroids may contribute to
dysregulation of the momoamine system [48], In animal models, Cortisol alters the
expression of 5HTla and 5HT2c receptors [49, 50], In humans, high morning Cortisol
contributes to downregulation of 5HT1 a receptors thereby reducing serotonin
neurotransmission and making depressive states more likely [51]. Animal and human
studies have also suggested that Cortisol may be toxic to hippocampal neurones and
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that this toxicity contributes to ongoing HPA dysregulation in depressive disorders
[17, 42, 52],
Although magnetic resonance imaging studies have demonstrated reduced
hippocampal volume in patients with major depression [53], this may either be a
reflection of pre-morbid vulnerability or a consequence of repeated episodes of illness
[54], Furthermore, it should be appreciated that although depressive disorders may
sometimes be associated with functional and structural abnormalities in the brain, they
probably occur not as a result of an abnormality within one particular region but
because of dysfunction within dynamic neural networks such as those connecting the
frontal cortex with areas such as the hippocampus, amygdala and thalamus [55, 56],
This area is explored in more detail later in this chapter within a review of the
literature of neurocognitive impairment in mood disorders.
The precise relationships between elevated Cortisol, aberrant monoamine
transmission and depressive neural circuitry remain to be fully worked out. Flowever,
on the basis of research to date, a simplified neurobiological model of the
pathophysiology of depression can be constructed (figure 2).
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1.1.4 Clinical presentation of depression in young adults
Depression varies widely in its clinical presentation. In adolescence and young
adulthood atypical symptoms are common whereas more classic melancholic
presentations appear to be relatively rare [57], Younger adults with depression also
tend to report more irritability and anxiety [58], When depression has begun early in
life and has recurred, it may be that the possibility of an emerging bipolar disorder
should be considered. Two case reports which are taken, with permission, from
patients participating in the current study are presented below to illustrate the clinical
presentation of depression in young adults.
Case report 1 'Anxious-hostile' presentation of depression in young adult
A 21 year-old university student was assessed by a psychiatrist on an orthopaedic
ward two days after a violent suicide attempt. He had jumped fonn a height of 60
metres sustaining a broken leg, multiple cuts, severe bruising and a minor head injury.
He had taken the decision to kill himself after two weeks of escalating anxiety,
irritability, disturbed sleep and agitation in the lead up to an important set of exams.
He denied suffering from low mood, anhedonia, fatigue or changes in his appetite.
He had strong obsessional and perfectionistic traits in his personality and had become
convinced that, despite studying extremely hard, he was destined to fail his exams and
that life was no longer worth living. He had taken the decision to kill himself only a
few hours before the suicide attempt. Twelve months previously he had been
admitted briefly to a psychiatric ward following an impulsive overdose of
antidepressant medication. This previous episode of depression had also been
characterised by symptoms of anxiety and irritability rather than more classic
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depressive features. After transfer from the orthopaedic ward he made a good
recovery as an inpatient on a general psychiatric ward and eventually responded well
to venlafaxine at a dose of 225mg per day.
This case is an example of depression in a young man with prominent anxiety,
irritability and impulsivity. Although this kind of presentation is well recognised in
adolescent populations [58], it does not fit easily into our current adult ICD-10 and
DSM-IV diagnostic classifications. Depressions characterised by irritability and
hostility may be misinterpreted by clinicians as personality dysfunction and can be
associated with dangerous impulsive behaviour and potentially lethal acts of self-
harm.
Case report 2 Possible bipolar depression in a young adult
A 20 year-old woman was referred by her GP to the psychiatrist because she
described mood swings. She gave a four-month history of feeling depressed and
irritable with excessive fatigue, overeating, weight gain and hypersomnia. She was
also drinking heavily, on average over 70 units of alcohol per week. She felt that she
first had problems with her mood at the age of 12 when she became over-active and
disruptive at school, having previously been a reserved and conscientious pupil. Over
the years she described several different periods in her life when her mood seemed to
switch suddenly between episodes of depression and short-lived periods of euphoria
with overactivity and decreased need for sleep. These periods of elevated mood
always lasted less than 2 days and tended to give way to longer periods of low mood
and irritability. She denied ever having harmed herself but had been admitted to
hospital three times as a teenager because of excessive alcohol consumption. She had
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a strong family history of affective disorder with both parents and an elder brother
suffering from MDD. The impression was that she was currently suffering from an
episode of MDD against a background of significant mood instability and
longstanding alcohol misuse. There was nothing in her history or presentation to
suggest that she had a personality disorder. She was treated with sodium valproate, a
mood stabiliser, up to a dose of 800 mg per day and made a good symptomatic
recovery within four weeks.
This is a case of depression characterised by excessive fatigue, hyperphagia,
weight gain and hypersomnia. This pattern of symptoms is described as 'atypical'
depression in DSM-IV and may be more common in bipolar disorder than in recurrent
unipolar disorder [59, 60]. Even though this patient does not meet the DSM-IV
criteria for bipolar affective disorder, that is, periods of depression alternating with
hypomania of at least four days duration, she describes considerable mood instability
and appears to have reacted in an adverse way to antidepressants. Recognition of a
possible bipolar depression in this case rather than unipolar depression may have
important implications for future pharmacological treatment choices, particularly
because antidepressants may have the potential to act as mood destabilisers in a
proportion of patients with a bipolar disorder by triggering mania, mixed affective
states and rapid-cycling. In a recent review of data from published reports and
clinical trials, Goldman and Truman estimated that between 25% and 33% of bipolar
patients were inherently susceptible to antidepressant-induced manias [61].
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1.2 Classification of affective disorders
As with most diagnostic categories in psychiatry, the classification of affective
disorders remains a work in progress. At the present time, the two most widely used
classifications are the ICD-10 Classification of Mental and Behavioural Disorders
published by the World Health Organisation (abbreviated to ICD-10) [62] and the
Diagnostic and Statistical Manual, fourth revision, of the American Psychiatric
Association (DSM-IV) [63],
1.2.1 Classification of depression and bipolar disorder
Both ICD-10 and DSM-IV are organised as a series of categorical diagnoses. In ICD-
10 the major categories of mood disorder are manic episode (F30), bipolar affective
disorder (F31), depressive episode (F32), recurrent depressive disorder (F33) and
persistent mood disorders (F34).
The criteria for a depressive episode in ICD-10 are outlined in figure 3. For
DSM-IV, a major depressive episode (MDE) is diagnosed according to the criteria
outlined in figure 4. Both ICD-10 and DSM-IV use a checklist of the same core
depressive symptoms: a minimum number of depressive symptoms is required to be
present over a two week period. ICD-10 also permits grading of the severity of the
depressive episode as mild, moderate or severe depending on the number of
depressive symptoms present. In DSM-IV, at least 5 depressive symptoms over the 2
week period are required for the diagnosis of a major depressive episode (MDE). It
can be seen that although both systems are essentially categorical, ICD-10 also allows
for some dimensional expression of severity.
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Figure 3. Depressive episode (ICD-10) [62]
A General criteria (G) for a depressive episode:
GI lasts for at least 2 weeks
G2 no history of hypomanic or manic symptoms
G3 episode is not attributable to psychoactive substance use or any organicity
B At least two of the following three symptoms must be present:
1. depressed mood that is definitely abnormal for the individual, present for most of the day
almost every day, largely uninfluenced by circumstances, and sustained for at least 2 weeks.
2. loss of interest or pleasure in activities that are normally pleasurable.
3. decreased energy or increased fatigability
C Additional symptoms form the following list (mild depressive episode, at least 4 in total; moderate
depressive episode, at least 6 in total; severe depressive episode, at least 8 in total).
1. loss of confidence or self-esteem
2. unreasonable feelings of self-reproach or excessive or inappropriate guilt
3. recurrent thoughts of death or suicide, or any suicidal behaviour
4. complaints or evidence of diminished ability to think or concentrate, such as indecisiveness or
vacillation
5. change in psychomotor activity, with agitation or retardation (either subjective or objective)
6. sleep disturbance of any type
7. change in appetite (decrease or increase) with corresponding weight change
D A fifth character may be used to specify the presence or absence of the 'somatic syndrome' which is
defined as at least 4 of the following symptoms:
1. marked loss of interest in activities that are normally pleasurable
2. lack of emotional reactions to events or activites that normally produce an emotional response
3. waking in the morning 2 hours or more before the usual time
4. depression worse in the morning
5. objective evidence of marked psychomotor retardation or agitation (remarked on or reported
by other people)
6. marked loss of appetite
7. weight loss (5% or more of body weight in the past month)
8. marked loss of libido
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Figure 4. Major Depressive Episode (DSM-IV) [63]
In the same 2 weeks, the patient has had 5 or more of the following symptoms, which are a definite change from
usual functioning. Either depressed mood or decreased interest or pleasure must be one of the five.
1. Mood. For most of nearly every day, the patient reports depressed mood or appears depressed to others.
2. interests. For most of nearly every day, interest or pleasure is markedly decreased in nearly all activities
(noted by the patient or by others).
3. Eating and weight. Although not dieting, there is a marked loss or gain of weight (such as five percent
in one month) or appetite is markedly decreased or increased nearly every day.
4. Sleep. Nearly every day the patient sleeps excessively or not enough.
5. Motor activity. Nearly every day others can see that the patient's activity is agitated or retarded.
6. Fatigue. Nearly every day there is fatigue or loss of energy.
7. Self-worth. Nearly every day the patient feels worthless or inappropriately guilty. These feelings are not
just about being sick; they may be delusional.
8. Concentration. Noted by the patient or by others, nearly every day the patient is indecisive or has
trouble thinking or concentrating.
9. Death. The patient has had repeated thoughts about death (other than the fear of dying), suicide (with or
without a plan) or has made a suicide attempt.
Notes:
• These symptoms cause clinically important distress or impair work, social or personal functioning.
• They don't fulfil DSM-IV criteria for Mixed Episode.
• This disorder is not directly caused by a general medical condition or the use of substances, including
prescription medications.
• Unless the symptoms are severe (defined as severely impaired functioning, severe preoccupation with
worthlessness, ideas of suicide, delusions or hallucinations or psychomotor retardation), the episode has
not begun within two months of the loss of a loved one.
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1CD-10 and DSM-IV differ more substantially from each other in terms of the
diagnostic criteria for bipolar affective disorder (BPAD). The major categories of
BPAD in ICD-10 are: current episode hypomanic (F31.0); current episode manic with
(F31.2) or without (F31.1) psychotic symptoms; current episode mild or moderate
depression (F31.3); current episode severe depression with (F31.5) or without (F31.4)
psychotic symptoms; current episode mixed (F31.6); currently in remission (F31.7);
and 'other' bipolar disorders (F31.8). As with the approach to diagnosing depression,
ICD-10 uses a checklist of hypomanic symptoms and permits grading of the severity
of both the hypomanic/manic episodes and the depressive episodes as mild, moderate
or severe and with or without the somatic syndrome or psychotic symptoms.
Figure 5. Core manic symptoms in ICD-10 and DSM-IV
Manic symptom DSM-IV ICD-10
Elevated mood + +
Irritable mood + +
Increased self esteem or grandiosity + +
Decreased need for sleep + +
Increased talkativeness + +
Flight of ideas + +
Distractibility + +
Increased social activity or contacts + +
Psychomotor agitation + +
Risk-taking behaviour + +
Increased sexual activities +
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As outlined in figure 5, both ICD-10 and DSM-IV use essentially the same checklist
of core manic symptoms to diagnose hypomania and mania ('increased sexual
activities" is included in DSM-IV within the category of'increased risk taking
behaviour").
In ICD-10, hypomania is considered to be a lesser degree of mania lasting
'several days' and causing 'considerable interference with work or social activity'.
By contrast, DSM-IV stipulates that hypomania occurs 'without marked social or
occupational dysfunction' (leading to a diagnosis of bipolar II disorder, figure 6).
Full mania in DSM-IV refers to any persistent elevation of mood lasting more than a
week that causes functional impairment (bipolar I disorder, figure 7). These subtle
differences between the two classifications mean that many patients who under ICD-
10 would be considered to have hypomania (that is, having hypomanic symptoms that
cause interference with work or social activity) would actually be excluded from a
DSM-IV diagnosis of hypomania because of this functional impairment and would be
considered to have DSM-IV mania.
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Figure 6. DSM-IV criteria for a hypomanic episode
A) A distinct period of persistently elevated, expansive or irritable mood, lasting throughout at least 4 days, that is
clearly different from the usual nondepressed mood.
B) During the period of mood disturbance, three (or more) of the following symptoms have persisted (four if the
mood is only irritable) and have been present to a significant degree:
1) inflated self-esteem or grandiosity
2) decreased need for sleep (e.g., feels rested after only 3 hours of sleep)
3) more talkative than usual or pressure to keep talking
4) flight of ideas or subjective experience that thoughts are racing
5) distractibility (i.e.. attention too easily drawn to unimportant or irrelevant external stimuli)
6) increase in goal-directed activity (at work, at school, or sexually) or psychomotor agitation
7) excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g.,
engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)
C) The episode is associated with an unequivocal change in functioning that is uncharacteristic of the person when
not symptomatic.
D) The disturbance in mood and the change in functioning are observable by others.
E) The mood disturbance not severe enough to cause marked impairment in social or occupational functioning, or
to necessitate hospitalization, and there are no psychotic features.
F) The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication
or other treatment) or a general medical condition (e.g., hyperthyroidism)
Note: Hypomanic-like episodes that are clearly caused by somatic antidepressant treatment (e.g., medication,
electroconvulsive therapy, light therapy) should not count toward a diagnosis of Bipolar II disorder.
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Figure 7. DSM-IV criteria for a manic episode
A) A distinct period of abnormally and persistently elevated, expansive or irritable rnood. lasting at leasl 1 week
(or any duration if hospitalisation is necessary)
B) During the period of ntood disturbance, three (or more) of the following symptoms have persisted (four if the
mood is only irritable) and have been present to a significant degree:
1) inflated self-esteem or grandiosity
2) decreased need for sleep (e.g.. feels rested after only 3 hours of sleep)
3) more talkative than usual or pressure to keep talking
4) flight of ideas or subjective experience that thoughts are racing
5) distractihi 1 ity (i.e., attention too easily drawn to unimportant or irrelevant external stimuli)
6) increase in goal-directed activity (at work, at school, or sexually) or psychomotor agitation
7) excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g.,
engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)
C) The symptoms do not meet criteria for a Mixed Episode
D) The mood disturbance is sufficiently severe to cause marked impairment in occupational functioning or in usual
social activities or relationships with others, or to necessitate hospitalization to prevent harm to self or others, or
there are psychotic features.
II) Ihe symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication
or other treatment) or a general medical condition (e.g.. hyperthyroidism)
Note: Manic-like episodes that are clearly caused by somatic antidepressant treatment (e.g.. medication,
electroconvulsive therapy, light therapy) should not count toward a diagnosis of Bipolar 1 disorder.
34
1.2.2 The bipolar spectrum concept
In recent years there has been renewed interest in the concept of a mood disorder
spectrum. It has been suggested that diagnostic systems such as DSM-IV fail to
detect a significant proportion of recurrently depressed patients with mild bipolar
features who may be more usefully considered to have a 'soft bipolar1 or 'bipolar
spectrum" disorder. It is also the case that failure to recognise early bipolar disorders
can delay treatment and worsen prognosis. Although this debate was started over 20
years ago by authors such as Akiskal, it has gathered momentum in recent years
because of longitudinal follow up studies and re-evaluations of existing
epidemiological data. This controversial area of nosology also has an important
historical dimension.
Historical considerations
Emil Kraepelin created a broad view of manic-depressive insanity which
encompassed not only less severe, attenuated forms but also most of the domain of
major depressive disorders [64], Several important studies in the second half of the
last century divided this unitary model of affective disorders into unipolar and bipolar
disorders. In the 1950s, Leonard observed from his cohort of patients with recurrent
depression that those who also had a history of mania tended to report more mania in
their families than patients who only suffered from depressive episodes [651. In the
1960s Angst [66] and Perris [67] provided independent family history data to support
this. Several lines of evidence subsequently supported the validity of a unipolar-
bipolar division: twice as many women as men appeared to suffer from unipolar
depression whereas the ratio in bipolar disorder was 1:1; bipolar subjects tended to
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have an earlier age of onset; and mortality (mostly through suicide) was consistently
higher in the bipolar group [68], This dichotomous conceptualisation of unipolar
versus bipolar disorder is reflected today in the ICD-10 and DSM-IV definitions
discussed above.
Although ICD-10 and DSM-IV have undoubtedly been of considerable value
in clinical practice and research, it may also be the case that they fail to capture the
complexity of many psychiatric presentations. By virtue of their multifactorial
aetiology, most psychiatric disorders tend to present clinically along a dimension, or
spectrum, of severity. For mood disorders, one of the consequences of this has been
the proliferation of a large collection of diagnoses. It has been suggested that patients
with mood disorders are better conceptualised as lying somewhere on a spectrum of
severity ranging from dysthymia at one end to full-blown manic-depressive psychosis
at the other (figure 8) [68], Under this kind of model, classic manic-depression
(bipolar I in DSM-IV) would be a relatively infrequent presentation of the broad
clinical spectrum of affective illness.
Figure 8. The affective spectrum |68J
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Single episode of depression





Bipolar affective disorder type II (hypomania + depression)
Bipolar affective disorder type I (mania + depression)
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In a similar proposal for the bipolar spectrum, Angst and Gamma have suggested a
diagnostic model that shows a continuum from purely depressive to purely manic
symptoms along a horizontal plane and a gradient of symptom severity along a
vertical plane (figure 9) [69]. Three subtypes of bipolar I disorder are recognised:
pure mania (M); predominant mania with mild depression (Md); and severe mania
with severe depression (MD). Between the purely depressive disorders and the
bipolar 1 subtypes lies bipolar II disorder, characterised by major depressive episodes
with hypomania (Dm). This spectrum concept does not reject the DSM-IV or ICD-10
categories, but provides a broader range of symptoms allowing for the possibility of
unclear distinction between different DSM mood categories.
Figure 9. Subtypes of the bipolar spectrum suggested by Angst and Gamma [69]
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Epidemiology ofbroadly-defined bipolar disorder
Prevalence rates of bipolar disorders in the population depend to some degree on the
choice of diagnostic criteria applied to patients with recurrent depression. Central to
this issue is the correct definition of hypomania, which is currently the subject of
considerable debate. Three particular areas of controversy are: the minimum duration
criterion for hypomanic symptoms (currently 4 days in DSM-1V); the validity of the
stem criteria (elevated, expansive or irritable mood); and the correct number of
hypomanic signs and symptoms required for a diagnosis of hypomania (currently
three or four) (figure 6).
The minimum duration required for a diagnosis of hypomania has changed
significantly over the years. In the Research Diagnostic Criteria it was 2 days [70], in
DSM-III and DSM-III-R it was not specified, and in DSM-IV it has been set at 4
days. Within the last few years, a group of bipolar experts have recommended
reverting back to the threshold of 2 days [71]. The validity of elevated, expansive or
irritable mood, the stem criterion A of DSM-IV hypomania, has also recently been
questioned. It has been suggested that 'behavioural activation' or periods of
overactivity should be given at least the same degree of importance in diagnostic
terms as extreme mood symptoms [72], Finally, at the time of writing, the threshold
of three or four out of seven signs and symptoms required for a diagnosis of
hypomania has yet to be formally validated.
It is very difficult to assess hypomania in the general population and in
depressed patients who tend to be unaware of their elevated mood changes. Unlike
most depressives, hypomanic subjects seldom complain of or suffer from their shifts
in energy, activity and sleep. It is well known that such changes are more likely first
to be picked up and recognised by family and friends. Many of the epidemiological
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studies carried out to date have had the disadvantage of assessing symptoms cross-
sectionally without corroborative history form patients' families.
Using the Zurich cohort of 4547 young adult subjects, who have now been
formally assessed six times between 1978 and 1999, Angst and colleagues recently
tested the diagnostic criteria of DSM-IV hypomania and attempted to develop and
validate criteria for softer expressions of bipolar II disorder [73], Clinical validity
was assessed by family history, illness course and clinical characteristics, including
the association between depression and substance abuse. Three sets of criteria for
hypomania were applied to the cohort: DSM-IV hypomania; Zurich 'strict' criteria for
hypomania; and Zuirch 'broad' criteria for hypomania. The Zurich 'strict' criteria
stipulated that patients suffered from euphoria, irritiability or overactivity, presented
with at least 3 of the 7 DSM-IV symptoms of hypomania, had hypomanic symptoms
of at least 1 day and experienced negative consequences of hypomania. The 'broad'
criteria also stated that patients had euphoria, irritability or overactivity; however,
patients had to present with only at least 2 DSM-IV symptoms of hypomania, had no
minimum duration of hypomanic symptoms and had no requirement to have
experienced negative consequences of hypomania. The prevalence of bipolar II
disorder in this cohort was found to be 2% under DSM-IV criteria, 5% under Zurich
'strict' criteria and 11% under Zurich 'broad' criteria. Using the broad criteria
suggested that up to 50% of the patients with a major depressive episode may in fact
have had bipolar II disorder.
Several additional reports support the finding of a more prevalent and
clinically significant spectrum of bipolar disorders. Longitudinal studies of bipolar
patients have identified that there are no differences in terms of features such as age at
onset, family history of mania or depression and chronicity between patients who
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experience hypomanic symptoms for short periods (less than 4 days) compared to
patients who have hypomanic symptoms of longer duration [71, 74]. When the
duration criterion for hypomania is reduced from 4 to 2 days, the prevalence rate for
bipolar disorder rises from 1% to around 5% [75, 76]. Furthermore, when patients
with a diagnosis of DSM-IV major depressive disorder (MDD) are systematically
assessed for a past history of manic symptoms, 45% satisfy diagnostic criteria for a
bipolar disorder [77]. It is also notable that levels of psychosocial impairment and
service utilisation are similar between patients with broadly-defined bipolar illness
and those diagnosed using DSM-IV criteria [76], As noted above, this increase in
bipolar disorder prevalence occurs at the expense of recurrent depressive disorders,
suggesting that between 25% and 50% of all patients with recurrent depression may in
fact be part of a bipolar group [69, 78, 79],
Criticisms of the bipolar spectrum concept
Although the concept of a broadened bipolar spectrum has gained some prominence
in recent years, it must be noted that this area remains controversial. At the time of
writing, a consensus has still to be reached on the correct approach to the assessment
and diagnosis of bipolar spectrum conditions. Some authors hold what might be
considered to be an extreme view in suggesting that almost all recurrently depressed
patients are to some degree bipolar [79-81].
Akiskal and Pinto have suggested that several distinct categories of bipolar
disorder exist along a spectrum of severity [82], These diagnoses have been
numbered from bipolar type I to type IV, depending on factors such as previous
hospitalisation, a family history of mania, antidepressant-associated hypomania and
hyperthymic temperament. In general terms, these categories have not gained
40
widespread acceptance within research and clinical fields. Many clinicians appear to
be uncomfortable with excessive sub-typing of affective disorders.
Baldessarini has argued that classic bipolar disorder is probably as close to a
"disease" as we have in modern psychiatry and that widespread acceptance of
broadened definitions of bipolarity run the risk of trivialising the core concept [83],
This view has important implications for biological research into bipolar disorder,
including neuropsychological, imaging and genetic studies. It may be the case that
research in the genetic field in particular would benefit from the study of more
homogeneous and strictly defined sub-types of bipolar disorder (for example, such as
puerperal mania [84], On the other hand, it could be also be argued that most patients
with bipolar disorder, as with schizophrenia, are likely to have inherited several
different genetic risk factors and that a full understanding of how these factors interact
to influence the clinical presentation can only proceed by studying the disorder along
a broad clinical spectrum.
Predicting bipolar outcome in apparently unipolar depression
Several factors appear to be associated with conversion to bipolar disorder from
unipolar depression. In a three year prospective follow up of 206 consecutive
depressed outpatients with no prior history of bipolar disorder, 41 patients (20%)
developed an episode of mania [85], Several variables in this study were associated
with bipolar outcome including: depressive episodes of acute onset, frequent
recurrence and of brief duration; a positive family history for bipolar disorder; post¬
partum depression; psychomotor retardation or atypical features; and antidepressant-
associated hypomania. The strongest associations with bipolar outcome were for a
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positive family history of bipolar disorder and antidepressant-associated hypomania,
with positive predictive values of 94% and 100% respectively [85],
Some of these findings have been replicated. In a study of 203 consecutive
mood disorder outpatients followed up for between 3 and 6 months, Benazzi reported
that bipolar depressives were 3 times more likely to experience antidepressant-
associated hypomania than unipolar depressives (17.3% versus 3.8%) [86], In this
study early age at onset of depression and the presence of atypical features were
associated with bipolar II disorder and antidepressant-induced switching. In a small
study of 27 patients with unipolar depression compared to 27 age and sex-matched
patients with bipolar depression, Mitchell and colleagues found that although the two
groups did not differ significantly in terms of most of the core symptoms of
depression, the bipolar depressed group tended to exhibit less psychomotor slowing,
more agitation, more atypical symptoms and had shorter episodes of depression [87],
In the National Institutes of Mental Health (NIMH) collaborative depression
study, where patients were followed for 11 years, 48 out of 559 patients converted
from unipolar depression to bipolar II bisorder [88], Early age at onset of depression
(defined as onset before age 25), atypical depressive symptoms and recurrent
depressive episodes at study entry predicted a switch from unipolar depression to
bipolar II disorder. The large French EDIPEP study also showed that early age at
onset differentiated bipolar II patients from unipolar patients [78).
A comparison of 39 bipolar I patients with age and sex-matched unipolar
patients found that bipolar depressed patients were significantly more likely to have
experienced an episode of psychotic depression in the past [59], Goldberg and
colleagues conducted a 15-year follow-up of 74 young adults hospitalised for severe
unipolar depression and found that 27% subsequently developed hypomania, with an
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additional 19% experiencing at least one episode of full-blown mania [89], In this
study the presence of mood congruent psychotic symptoms, such as auditory
hallucinations and delusional beliefs, during the index depressive episode were
strongly predictive of bipolar disorder, with eight out of ten patients with psychotic
depression eventually becoming bipolar during the 15 year follow-up period [89],
Also of note from this study was that patients with a positive family history of mania
were at high risk of a bipolar outcome.
A number of other variables have been associated with bipolar outcome in
apparently unipolar patients, although the evidence for these variables is weaker than
the factors above. These variables include a premorbid hyperthymic personality,
which in some studies [71] but not in others [90] has been associated with a family
history of bipolar disorder. Studies of the natural history of mood disorders suggest
that bipolar depressive episodes tend to be shorter than unipolar depressive episodes
(with mean duration of 3-6 months compared to 6-12 months) [68], Mostly from
clinical observation, it has also been suggested that acute but not prophylactic
response to antidepressants (referred to as 'antidepressant wear off) and a history of
non-response to multiple courses of antidepressants are additional factors that may be
predictive of ultimate bipolar outcome [68],
Ghaemi and colleagues recently suggested that some of the above features
could form the basis for a diagnosis of bipolar spectrum disorder (BSD) [91], BSD
would describe a disorder where patients do not meet the strict DSM-IV criteria for
bipolar disorder but who nonetheless have clinically significant bipolar features.
These criteria are outlined below in figure 10. They emphasise the importance of a
first degree family history of bipolar disorder and a personal history of antidepressant-
associated hypomania. As noted above, these two factors appear to have the strongest
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evidence in terms of being able to predict bipolar outcome. The remaining factors
outlined in figure 10 have less evidence in their favour and are therefore given much
less weight in terms of the diagnosis of BSD.
These are relatively new criteria and attempts to assess the validity of this
diagnosis are currently in progress in a number of centres across the world. In a
recent preliminary report, Ghaemi and colleagues applied the BSD criteria to 36
patients with bipolar I or II disorder and 37 unipolar depressives [92J. In a univariate
analysis they found that 7 of the 12 features in the BSD criteria were more likely to
occur in bipolar than unipolar patients. After adjusting for all predictors in a
multivariate regression model, the five most powerful predictors of bipolar disorder
were brief major depressive episodes, early age at onset, anti-depressant associated
hypomania, postpartum depression and atypical depressive symptoms [92], In this
study the strongest associations were for brief episodes of depression (less than 3
months duration), which had an odds ratio for predicting bipolar disorder of 48.3, and
early age at onset (less than age 25) which had an odds ratio of 23.3.
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Figure 10. Proposed diagnostic criteria for bipolar spectrum disorder (BSD) [93]
A at least one major depressive episode
B no spontaneous DSM-IV hypomanic or manic episodes
C either of the following plus two from D, or both plus one from D:
First degree relative with bipolar disorder
Antidepressant-associated mania or hypomania
I) if none from C, at least six of the following:
Hyperthymic personality
More than 3 depressive episodes
Brief major depressive episodes (less than 3 months)
Atypical depressive symptoms
Psychotic major depressive episodes
Early age of onset (less than age 25)
Postpartum depression
Antidepressant 'wear-off (acute but not prophylactic response)
Lack of response to more than 2 antidepressant trials
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Bipolar spectrum disorders in young adults
In most epidemiological studies the age at onset for unipolar major depression is in
the late 20s and early 30s, whereas the age at onset for bipolar disorder is consistently
identified as occurring between the mid-teens and mid-20s. From the large German
Health Interview and Examination Survey (GHS), Jacobi and colleagues have
recently demonstrated that 50% of bipolar disorder subjects report an onset before age
18, whereas the median age at onset for major depression is 30 (figure 11) [94],
Figure 11, Age of onset distributions for MDD and BPAD in the GHS [94],
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Both early age of onset in depression and severity of depressive episodes are
important factors in determining rates of ultimate progression to bipolar disorder.
Prepubertal-onset depression may be a strong marker for bipolar disorder, with some
studies finding that at least one third of depressed children will develop bipolar
disorder in adult life [95], In a seven-year prospective study of 28 outpatient
depressed adolescents Rao and colleagues detected a rate of bipolar outcome of
almost 20% [96],
Bipolar disorders tend to present initially in a depressive phase and usually
during adolescence or young adulthood [97], In keeping with the German Health
Survey above, the median age of onset of almost 3,000 patients recorded on the
Stanley Centre Bipolar Disorder Registry was calculated at 17.5 years [98], It is also
the case that there is often a long delay between the first presentation of a bipolar
disorder and diagnosis. In a study of 450 bipolar patients, Baldessarini and colleagues
found that mean length of time between first episode and maintenance treatment was
7.8 years [99j.
When one considers that rates of progression from adolescent depression to
bipolar disorder are in the region of 20% [96, 100], there would appear to be a strong
case for consideration of possible bipolar illness in all young adults presenting with
recurrent depressive episodes. However, to date this has been an under-studied area.
Although the study by Goldberg and colleagues mentioned above prospectively
followed young adults hospitalised with depression [89], there are very few studies
that have focussed on a cohorts of young adults with recurrent depression in
outpatient clinical settings. One of the main aims of this thesis will be to apply the
BSD criteria (as defined by Ghaemi and colleagues) to a cohort of young adults with
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recurrent depression and to examine the validity of the bipolar spectrum concept
this population both clinically and also in terms of neurocognitive function.
1.3 Neuroeognitive function in depression and bipolar disorder
Cognitive dysfunction is a central feature of mood disorders. Both ICD-10 and DSM-
IV consider cognitive impairment to be part of the diagnostic criteria for depression
and mania. This includes reduced concentration, attention and memory in depression
and reduced attention with distractibility in mania. Although it has long been clear
that these impairments are present during affective episodes, in recent years it has
been recognised that some will also persist upon clinical recovery, often with
significant implications for psychosocial functioning [101]. These abnormalities
occurring outwith episodes of illness may also provide useful information about the
pathophysiology of mood disorders. They can provide information about trait
abnormalities (allowing judgements to be made about the neural circuits likely to be
underlying mood disorders) as well as permitting assessments of the contribution
made by successive episodes of illness to long term psychological functioning.
Many of the studies carried out to date in this area present difficulties for
interpretation because they have tended to use populations of patients of differing
ages, gender distributions, depressive sub-type (for example, 'mixing in' bipolar and
unipolar depressives in the same study), stage of illness (both unwell and recovered)
and medication status. Furthermore, although many of the neuropsychological tests
used are claimed to represent discrete and anatomically defined functions, the frontal
lobes and temporal structures such as the hippocampus and amygdala clearly do not
operate in isolation. Strong reciprocal connections between prefrontal and temporo-
limbic circuits are well established and abnormalities at one or more points on these
circuits could produce many of the findings discussed below.
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It is also the case that at the time of writing there were no good quality
published studies that directly compare well matched euthymic bipolar patients with
euthymic unipolar patients and controls. As a result, most of the conclusions that can
be drawn about the differences between cognitive performance in bipolar disorder and
unipolar depression have to be extrapolated from case-control studies that compare
either bipolar patients or unipolar patients with controls. In reviewing this literature I
have organised a critique of the data into two categories: i) neurocognitive function in
patients with major depressive disorder and ii) neurocognitive function in patients
with bipolar disorder.
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1.3.1 Neurocognitive function in major depressive disorder
Although it had been previously well documented that cognitive impairment was part
of the clinical picture of depression [102], it has only been within the last 20 years
that studies have assessed the possibility that patterns of neurocognitive impairment in
depressed patients might help to identify aspects of the neural circuitry at the core of
the disorder.
In an early neuropsychological study, Austin and colleagues compared 40
patients with major depression to 20 age and education-matched controls on a broad
neuropsychological battery [103]. They found that depressed patients were more
impaired on the auditory verbal learning test. Interestingly, recall and recognition
were equally impaired suggesting that effort was not a major determinant of
performance. As expected, impairment was positively correlated with depressive
symptom scores, even after allowing for the effect of age [103]. This study also
found that depressed patients were impaired relative to controls on a test of executive
function (the Trail-making test, part B) and that this too was positively correlated with
symptom severity [104],
In a similar study of 15 patients with major depression assessed during a
depressive episode and compared to 15 age, sex and intelligence-matched controls,
Ilsley and colleagues found that the depressed patients were unimpaired relative to
controls on measures of short-term memory, recognition, semantic memory and
implicit memory. However, depressed patients had deficits in psychomotor speed and
in the free recall of material (both immediate and delayed). This selective recall
deficit suggests that material had been encoded successfully but that the patients were
impaired with regard to search and retrieval processes [105]. A potential limitation of
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this study was that 11 of the 14 patients were taking antidepressant medication at the
time of testing.
The issue of medication status as a confounding variable in
neuropsychological studies of depression was addressed recently by Porter and
colleagues (106], Forty-four patients with major depression, all of whom were
carefully assessed as medication free for at least 6 weeks before testing, were
compared to 44 demographically matched, healthy comparison subjects. As expected,
patients were impaired relative to controls across a broad range of cognitive domains,
including attention and executive function and visuospatial learning and memory.
Severity of depression correlated with learning and memory performance but not with
executive function. This study suggests that appreciable neurocognitive deficits occur
during depressive episodes even in medication free patients. Interestingly, in an
earlier published report on the same cohort of patients, this research group identified
significantly higher cortisol-DHEA ratios in the depressed patients than in the healthy
comparison subjects, suggesting that elevated cortisol-DHEA ratios may represent a
state marker of depressive illness and contribute to the associated deficits in learning
and memory [42],
It should be noted that not all studies of depressed patients have identified
neurocognitive impairments. In a large study of 123 depressed patients (who had
been medication free for 28 days) and 36 controls, Grant and colleagues failed to
detect widespread cognitive impairment apart from executive function deficits on the
Wisconsin Card Sort Test [107], However, this sample of patients, with a mean
Hamilton score of 16.7 and mean Beck's score of 17.3 appeared to represent quite a
mild clinical sample of depressed outpatients. It is also possible that by comparing
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123 patients with only 36 controls the power of this study to detect subtle differences
was diminished.
It is well documented that cognitive impairment (and hippocampal volume
loss) is more pronounced in older patients with depressive disorder [53, 108-110],
This may be explained by a number of factors, including a greater number of lifetime
depressive episodes (and the possibility of a cumulative toxic effect of
hypercortisolaemia) [110] or by the influence of microvascular insufficiency or deep
white matter hyperintensities in older patients [111, 112]. There remains debate about
the mechanism of hippocampal impairment in older depressives. Some studies
suggest that acquired biological factors such as microvascular disease may be more
important [113] whereas others have suggested that melancholic depressive episodes
(which are associated with hypercortisolaemia and which are more common in older
adults with depression) is the mechanism of hippocampal volume loss [53, 114].
To date, very few studies have focussed on younger cohorts of depressed
patients, although a recent study by MacQueen and colleagues attempted to address
this area by examining the function and volume of the hippocampus in a case-control
sample of young adults with depression [115]. Twenty never-treated, first-episode
depressed subjects were compared to seventeen subjects with a history of multiple
episodes of depression and to well matched controls. Hippocampal function was
assessed using neuropsychological tests of recollection memory and verbal memory,
and hippocampal volume was measured by magnetic resonance imaging. Both first-
and multiple-episode depressed groups had impaired hippocampal function as
assessed by neuropsychological testing, but only the group with multiple previous
episodes had evidence of reduced hippocampal volume. This suggests that reduced
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hippocampal volume does not pre-date illness onset but rather may be a consequence
of repeated episodes of illness.
Surprisingly, there is a relative paucity of studies examining cognitive
function in patients who have recovered from depression. Most of the
neuropsychological studies of euthymic or clinically remitted mood disordered
patients have been carried out in bipolar subjects (discussed below in the next
section). In one study of recovered patients with chronic MDD, Paradiso and
colleagues found that patients were more impaired than controls on measures of
visual-motor sequencing, executive function, and immediate memory and attention
[116]. However, there were important limitations to the design of this study: only 19
patients were compared to 19 controls; only male patients and controls were
compared; the threshold for euthymia was set as a Hamilton score of less than 14
(conventionally clinical remission is thought to be consistent with Hamilton scores
less than 9); and patients in the study were on relatively high doses of medication
(several were on a combination of benzodiazepines, lithium and an antidepressant).
Biringer and colleagues recently re-tested thirty patients who suffered from
recurrent major unipolar depression on tests of executive function two years after an
initial baseline examination [117], At baseline patients were depressed (average 17-
item HAM-D score 21.8) and at retesting they were partially or totally recovered
(average HAM-D score 8.2). There was a significant positive association between
improvement on the HAM-D and improvement of executive function. In those
patients with complete recovery, executive function was no longer different from the
baseline performance of healthy controls. This suggests that recovery from major
unipolar depression may be accompanied by a recovery of many aspects of executive
function to a normal level.
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In summary, the available evidence suggests that currently depressed patients
have impairments in the domains of memory, attention and executive function that are
to some degree influenced by age, severity of depressive symptoms and previous
illness course. These impairments do not appear to be necessarily a function of
reduced motivation or effort. Furthermore, they are present to a notable degree in
medication-free patients. So far, the evidence suggesting that cognitive impairments
persist to any significant degree in unipolar depression beyond clinical recovery is
less convincing - this is an area in need of further study.
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1.3.2 Neurocognitive function in bipolar disorder
Ncurocognitive impairments have been demonstrated across all three phases of
bipolar disorder (bipolar depression, euthymia and hypomania/mania) [118]. Perhaps
unsurprisingly, the severity of deficits are correlated with earlier age at onset, longer
duration of illness, more severe illness episodes and exposure to psychotropics [119].
Although a large number of studies in this area have now been published, many have
significant methodological limitations. Neurocognitive findings in each of the three
clinical phases of bipolar disorder are reviewed below.
Neurocognitivefunction in bipolar depression
Bipolar depression and unipolar depression appear to share a similar
neuropsychological profile. Although separate studies of unipolar depressives and
bipolar depressives compared to controls have identified similar patterns of
impairment in attention, memory and executive function [103, 106, 118], very few
studies have directly compared bipolar depressed patients with unipolars. Wolfe and
colleagues compared four groups on a test of verbal memory and a test of verbal
fluency: 20 normal controls, 20 unipolar depressed patients, 12 bipolar depressed
patients and 10 patients with Huntington's Disease [120]. They found that both
depressed patient groups performed less well than controls on verbal recall and
recognition and that bipolar patients were more impaired than unipolar patients on
both tasks. Interestingly, the performance of the bipolar patients was similar to that of
patients with Huntington's disease, suggesting significant subcortical dysfunction.
The diminished attention seen in bipolar depressed patients (an inattentive
response pattern with errors of omission) is similar to that seen in unipolar depressed
56
patients but is more pronounced [121]. In a relatively large study of consecutively
admitted young adult patients, Sweeney and colleagues compared 21 patients with
bipolar depression to 58 unipolar depressed patients, 14 manic patients and 51
controls on the computerised Cambridge Neuropsychological Test Automated Battery
(CANTAB) [122]. Although manic patients had widespread impairments across
verbal memory, attention and executive function domains, bipolar depressed patients
and unipolar depressed patients demonstrated only episodic memory impairment
relative to controls. As with the study conducted by Wolfe and colleagues [123], the
pattern of neuropsychological impairment was similar between bipolar depressives
and unipolar depressives.
As with unipolar depression, a number of hypotheses have been suggested to
account for the observed cognitive impairment in bipolar depression, including
reduced motivation, impaired concentration, slowness of movement and thought,
heightened anxiety and hypercortisolaemia. However, whether many these factors are
indeed major influences on performance depends to a large extent on whether the
observed deficits persist upon clinical recovery. This concept of enduring impairment
during phases of recovery in bipolar disorder is considered in detail later in this
chapter.
Neurocognitivefunction in hypomania and mania
Only a small number of studies have assessed the neuropsychological function of
hypomanic or manic patients, presumably because of the logistical difficulties in
assessing patients during this period of illness. Sax and colleagues used the
Continuous Perfomance Test (CPT), a widely used test of sustained attention, to
compare 17 manic patients and 13 patients with a mixed affective episode to 13
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healthy controls [124], Both manic groups performed significantly less well than
controls, and the mixed mania group performed less well than the pure manic group.
In contrast to the pattern of impaired attention seen in bipolar depressed patients
(errors of omission) [121], manic patients were characterised by impulsive errors of
commission. It is interesting to speculate that this may be reflected clinically in
patients with hypomania and mania by a propensity towards impulsivity and poor
decision making [125],
In a neuropsychological investigation of prefrontal cortical function in acute
mania using selected tests from the CANTAB, Clark and colleagues compared 15
manic patients with 30 normal controls and identified deficits in patients
predominantly in verbal memory and sustained attention [126],
The study quoted above by Sweeney and colleagues identified widespread
impairments across verbal memory, attention and executive function domains in
manic patients compared to controls [122], Similarly, Martinez-Aran and colleagues
compared 30 depressed bipolar patients, 34 manic or hypomanic bipolar patients, 44
euthymic bipolar patients (with euthymia defined as 6 months of remission, a
Hamilton depression scale score less than 9, and a Young Mania Rating Scale score
less than 7) and 30 healthy controls on a neuropsychological battery assessing
executive function, attention, and verbal and visual memory [127]. Unsurprisingly,
all three patient groups performed less well than controls across most of the tests.
Although both depressed and hypomanic/manic patients performed less well than
euthymic patients, there was no clear difference in performance in any of the domains
between the depressed bipolars and the hypomanic/manic bipolars.
In summary, the evidence suggests that hypomanic and manic patients have
neurocognitive impairments in both verbal memory and attention/executive function.
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Furthermore, these deficits appear to be more pronounced in manic patients with
mixed affective symptoms or psychotic symptoms [128],
Neurocognitive function in bipolar patients during euthymic intervals
For many years it was believed that euthymic or clinically recovered bipolar patients
had an absence of affective symptoms and a normal level of functioning between
episodes of illness. However, it has become clear that many bipolar patients will
continue to experience sub-syndromal symptoms between episodes of illness that can
impact significantly on their social and occupational functioning [129, 130].
A number of studies have now suggested that neurocognitive impairments are
present during illness remission. Ferrier and colleagues assessed attention, working
memory and executive function in three matched groups of subjects: good-outcome
patients with bipolar disorder (n=21); poor-outcome patients with bipolar disorder
(n=20); and controls (n=20) [101], All patients were in clinical remission, although
some had low levels ofdepressive symptoms. Patients performed worse than controls
on a number of neuropsychological tests but only the result for executive function
(specifically, executive control of working memory) remained significant when age,
premorbid 1Q and depressive symptoms were controlled for.
In a similar study that used a more rigorous definition of euthymia (clinical
remission for at least 4 months), Rubinsztein and colleagues found that compared to
controls clinically remitted bipolar patients had a relatively specific impairment in
memory (visuospatial recognition) and relatively unimpaired executive function
[131]. One interpretation of this finding is that the core deficit in euthymic bipolar
disorder lies at the level of temporal structures rather than at the frontal lobe, as
suggested by Ferrier and colleagues [101],
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In a comparison of 20 euthymic bipolar patients and 20 matched controls,
Cavanagh et al found that bipolar patients had impaired verbal memory with relatively
intact executive function [132], However, this study did not control for residual
affective symptoms in patients. By contrast, Clark and colleagues found in a similar
study that although euthymic bipolar patients were impaired on tasks of attentional set
shifting, verbal memory and sustained attention, only the sustained attention deficit
remained when mild affective symptoms were controlled for [133], In a prospectively
verified sample of 63 euthymic patients with bipolar disorder and 63 controls,
Thompson and colleagues reported a wide range of cognitive deficits, including both
verbal memory and executive dysfunction 1134], Patients in this study were assessed
for over a month as having been euthymic before testing. Salivary Cortisol levels
were also collected and were found not to be associated with the cognitive deficits.
In a recent functional magnetic resonance imaging study of euthymic bipolar I
patients maintained on lithium and compared to controls, Monks and colleagues used
two different working memory tasks to explore aspects of working memory function
[1351. They found that central executive function, rather than phonological loop
function, was the core working memory deficit, suggesting that failure to engage
fronto-executive function may be a fundamental neurocognitive deficit in bipolar
disorder. It will be interesting to see if this finding can be replicated in medication-
free patients.
Although factors such as previous illness severity, number of affective
episodes, current levels of mood symptoms and medication status may exert some
influence over cognitive performance in bipolar disorder, it may be that the observed
deficits in attention/executive function and declarative memory are a function of
genetic loading for mood disorder and that they represent trait abnormalities of the
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neural circuitry underlying bipolar disorder and depression. This hypothesis can be
tested in a number of ways, including twin and family studies, analyses of premorbid
functioning in early bipolar illness and assessments of the clinically well first degree
relatives of bipolar probands.
Gourovich and colleagues compared neuropsychological performance in seven
monozygotic twin pairs who were discordant for bipolar disorder and found that both
twins had mnemonic impairments as measured by the Wechsler Memory Scale
(WMS) and the California Verbal Learning Test (CVLT), although this study may be
confounded by the fact that some of the subjects were tested during an affective
episode [136]. In an MRI study of six monozygotic bipolar twins discordant for
bipolar disorder and compared to a control group of monozygotic twins with no
history of bipolar disorder, Noga and colleagues found that the right hippocampus
was smaller in the unwell bipolar twins, but that both ill and well twins had larger
caudate nuclei than their control counterparts, suggesting that this structure may be a
genetically determined risk factor for the development of bipolar disorder [137], The
role of genetic risk factors is also suggested by a recent finding that patients with
bipolar disorder who have a positive family history of psychosis performed worse
than patients with no such family history on tests of visual-motor processing and
attention [138],
Several retrospective case-control studies suggest that, as appears to be the
case in schizophrenia, patients with severe mood disorders have evidence of subtle
neurodevelopmental dysfunction in childhood. In a general population birth cohort,
Van Os and colleagues found that patients with affective disorders had been delayed
in reaching motor milestones and had higher rates of speech abnormalities than
normal controls [139], Similarly, higher rates of developmental impairments in
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language, motor and social functioning have been found in adolescents with bipolar
disorder or depressive psychosis relative to unaffected controls [140], In a
prospective study that followed 56 children with deficits in attention, motor control
and perception ('DAMP') and controls between the ages of 6 and 16, Hellgren and
colleagues found that the DAMP group had higher rates of psychiatric disorder,
especially major depression, at follow up [141],
Several studies have now identified neurocognitive abnormalities in the
unaffected family members of bipolar patients. In an examination of
neuropsychological performance in the family members of patients with
schizophrenia and bipolar disorder, Keri and colleagues found that the unaffected
relatives of the bipolar group had more verba! recall difficulties than a group of
unrelated controls [142], Zalla and colleagues have reported that both bipolar patients
and their unaffected relatives are impaired on the Stroop test, suggesting a trait deficit
in prefrontal attention and executive function [143], More recently, a study of 17
euthymic bipolar patients and 17 unaffected first degree relatives identified selective
deficits in declarative memory and executive control in relatives [144],
Taken together, the studies reviewed above suggest that the cognitive profile
of bipolar disorder may be characterised by persistent deficits in either declarative
memory abilities, executive function or both. Although previous illness course,
current affective symptoms and medication may play a role in these deficits, they may
also represent trait abnormalities that are closely related to genetic risk. In other
words, these neurocognitive impairments may reflect underlying endophenotypic
abnormalities that are central to the pathophysiology of bipolar disorder [145].
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1.3.3 Methodological considerations
It can be seen from the above that the literature of neuropsychological testing in mood
disorders as it currently stands has a number of limitations that will need to be
addressed in future studies. These limitations are now considered in more detail.
Medication effects
Neuropsychological studies on drug naive patients with mood disorder are relatively
rare because of the difficulties in recruiting patients who are medication-free. It may
also be unethical to conduct studies that require patients to be drug-free for long
periods. It is well documented that psychotropic medications may influence
performance on cognitive tests [146], Neuroleptics (particularly traditional
antipsychotics such a chlorpromazine) and benzodiazepines have been shown to have
a detrimental effect on cognitive function [147]. Antidepressants, especially those
with anticholinergic properties, have been associated with subtle deficits in
psychomotor speed and verbal memory [129, 148]. In some studies lithium has been
reported to have adverse effects on memory and psychomotor functioning [149]
whereas in others it has been shown to be relatively benign [150, 151 ]. During a 6
year follow-up period of lithium-treated bipolar patients, Engelsmann and colleagues
found no evidence of cognitive decline [151], More recently, the possibility has
emerged that mood stabilisers such as lithium and valproate may actually enhance
cognitive function through a neuroprotective action on neuronal tissue [152].
Even though several authors have suggested that the effects of psychotropic
medications are relatively minor, it must be acknowledged that even small effects
could substantially detract from the conclusions of many studies because the
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differences detected between patients and controls are often of quite a small
magnitude. It also the case that many patients will have been taking combinations of
psychotropic medications at varying doses over long time periods. The true effect of
combined medication (for example, antidepressants plus mood stabilisers) is currently
unknown.
Sample size and heterogeneity
Many studies in this field are underpowered because of small sample sizes. It is also
clear that when there are adequate numbers of patients and controls, it is often the
case that the patient group were heterogeneous in terms of age, clinical subtype and
previous course of illness. This is particularly important in those studies that include
patients with psychotic symptoms and non-psychotic patients in the same group.
Even though alcohol abuse occurs in up to 50% of patients with bipolar disorder [68]
(and is well recognised as a cause of cognitive impairment), too few studies stipulate
a history of significant alcohol misuse as an exclusion criterion.
Effect sizes and degree offunctional impairment
Although neuropsychological studies often detect statistically significant differences
between patients and controls, many of these differences are relatively small and may
not necessarily be related to significant functional deficits. Over the last few years it
has increasingly been the case that measures of effect sizes are reported so that a more
meaningful estimation of the degree of cognitive deficit can be appreciated [ 134],
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The correct definition ofeuthymia
Unfortunately, until relatively recently, many studies have used definitions of
euthymia that may be inadequate. The true definition of sustained clinical recovery in
bipolar disorder remains extremely difficult, especially in light of recent evidence
suggesting that residual affective symptoms (and functional impairment) is common
throughout the natural history of bipolar disorder [74], Until an accepted definition of
euthymia is agreed, it seems that current best practice would be to use samples of
patients who have been prospectively assessed (both subjectively and objectively) as
being in full clinical remission for at least a period of 3 months.
Diagnostic considerations
As discussed in the first half of this chapter, there is debate about the boundaries
between recurrent major depression, bipolar spectrum disorder, bipolar II disorder and
bipolar I disorder. Many neuropsychological studies of depression and bipolar
disorder have 'mixed in' unipolar depressives with bipolar I depressives and bipolar II
depressives. Future studies may benefit from the use of more diagnostically
homogeneous patient groups.
Do neuropsychological impairments reflect disease process or trait deficits?
Some of the studies noted above have identified correlations between illness variables
such as number of previous affective episodes or more severe affective episodes (eg,
psychotic episodes) and degree of neurocognitive impairment [119, 132]. This has
been hypothesised as being due to an ongoing disease process, for example, the toxic
effects of hypercortisolaemia during acute exacerbations having a 'scarring' effect on
vulnerable brain regions such as the hippocampus [132], However, as also discussed
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above, there is also converging evidence from a number of studies that these
abnormalities may represent trait, or endophenotypic, deficits. Future 'high risk"
paradigms (for example, assessing clinically well first degree relatives or prodromal
patients), as well as prospective neuropsychological assessments on patients, will be
required to separate out the effects of'state' and 'scar" from trait or genetic
vulnerabilities.
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1.3.4 Implications of neurocognitive impairment for the aetiology and
pathophysiology of depression and bipolar disorder
Despite limitations within many of the neuropsychological studies of mood disorder,
some of the more robust findings (that is, attention/working memory, executive
function and declarative memory deficits) are supported by neuroimaging studies.
One of the most consistent imaging findings in mood disorders has been a
reduction in brain volume and blood flow within the dorsolateral prefrontal cortex in
both unipolar and bipolar disorder [153-156]. The anterior cingulate cortex has been
consistently implicated in functional imaging studies of depression [157, 158] and
reduced size of the hippocampus has been identified for both depression and bipolar
disorder [159-161]. Although subcortical and medial temporal structures such as the
basal ganglia and amygdala are reduced in size in unipolar depressive disorder [154,
162], several studies have demonstrated an enlargement of these structures in bipolar
disorder [161. 163]. This difference raises the possibility that subcortical
abnormalities in mood disorders may be responsible for the phenotypic distinction
between bipolar disorder and unipolar disorder. It has been suggested that unipolar
depression and bipolar disorder may share a common 'underdevelopment' of the
prefrontal region, leading to a loss of inhibitory cortical control over limbic emotional
networks [56], The expression of a mood disorder as either unipolar or bipolar may
then be dependant upon whether these limbic structures (basal ganglia or amygdala)
are smaller or larger than normal [164].
The principal goal of neuropsychological and neuroimaging research in mood
disorders is to understand the fundamental abnormalities of neural circuitry that are
dysfunctional in individuals who suffer from depressive disorders. From the studies
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reviewed above, it is possible to speculate on the neurocircuitry involved in
depressive disorders. Soares and Mann [165] have suggested that the brain regions
outlined in figure 12 are involved in the modulation of mood and that two
interconnecting circuits are central to the pathophysiology of mood disorders. These
are a 'limbic-thalamic-cortical' circuit (connecting the amygdala, the mediodorsal
thalamic nucleus, and the medial and ventrolateral prefrontal cortex) and a 'limbic-
striatal-pallidal-thalamic-cortical' circuit (connecting the limbic system with the
basal ganglia and thalamus). Affective disturbance is thought to result from
dysfunction at one or points on these circuits.
Neuropsychological research in mood disorders also has the potential to
contribute to aetiological investigations, for example, by correlating endophenotypic
cognitive deficits with putative genetic risk factors. Of particular relevance for this
thesis is the question of whether neurocognitive performance in mood-disordered
patients can be used to assess the validity of both established and novel diagnostic
criteria for depression and bipolar spectrum disorder.
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Figure 12. Brain regions implicated in the regulation of mood
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1.4 Objectives
In the introduction above I have reviewed the aetiology, pathophysiology,
classification and neuropsychology of mood disorders. In terms of classification, I
have highlighted the concept of a broadened bipolar spectrum, including a discussion
of the background to the recent proposal of novel diagnostic criteria for bipolar
spectrum disorder (BSD) (figure 10) [93], Factors such as early onset of depression
(that is, in adolescence or young adulthood) and severe depressive episodes are
strongly associated with both high genetic loading for mood disorder and a high risk
for lifetime progression to bipolar disorder. It follows that a useful sub-group of
depressive? to study with regards to the validity of a broadened bipolar spectrum is a
cohort of young adults with early-onset recurrent depression.
1.4.1 Prevalence and validity of BSD criteria in young adults with early-onset
recurrent depression
The first aim of this thesis is to assess the clinical presentation of recurrent depression
in young adults with particular reference to the prevalence of bipolar spectrum
disorders within this group. An attempt will then be made to assess the validity of the
BSD criteria according to clinical parameters. The classic guidelines for establishing
the validity of psychiatric diagnoses proposed by Robins and Guze will be used [ 166J.
These include: clinical phenomenology; clinical course; family history; and treatment
response. Patients with DSM-IV defined BPAD will be compared to BSD patients
(defined according to figure 10) and DSM-IV MDD patients on each of these validity
criteria.
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1.4.2 Neurocognitive function in young adults with MDD and BSD
In reviewing the neurocognitive literature on mood disorders, there appears to be
good evidence that trait deficits in attention, executive function and declarative
memory are present in both unipolar depression and bipolar disorder. Furthermore,
these traits are more prominent in bipolar disorders than unipolar disorders, perhaps
as a consequence of higher genetic loading for mood disorder in the bipolar group
(although, as discussed above, there is debate about the degree to which these deficits
are truly endophenotypic because of factors such as previous illness course and
residual mood symptoms). A current deficiency in the neuropsychological literature
of mood disorders is the paucity of studies that directly compare well-matched groups
of young unipolar and bipolar patients, especially during periods of euthymia.
Idle second aim of this thesis is therefore to provide a comparison of
neurocognitive performance between euthymic young adults with DSM-IV recurrent
MDD. euthymic young adults with bipolar spectrum disorder (BSD) and well-
matched young adult controls. If one accepts that young adults with recurrent
depression who appear to have an early bipolar illness are likely to have a strong
genetic predisposition to mood disorder, this study can add to the debate about the
relative contributions made to cognitive impairment in mood disorders by genetic risk
factors and/or clinical factors such as illness severity or repeated episodes of illness.
Also as part of this neuropsychological study, I will consider the implications
for the concept of a broadened bipolar spectrum of the similarities and differences in
neurocognitive performance between young patients with DSM-IV major depression
and young adults with BSD. This will permit a consideration of whether cognitive
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2.1 Outline of study
The primary aims of this study were two-fold: firstly, to provide a detailed clinical
description of recurrent depression in young adults with particular reference to bipolar
spectrum disorders; and secondly, to perform a neurocognitive study comparing
euthymic young adults with major depressive disorder (MDD), bipolar spectrum
disorder (BSD) and controls. This work was carried out in the Division of Psychiatry
at the University of Edinburgh between 2002 and 2004.
2.2 Recruitment of patients and controls
Figure 13 outlines how different stages of this study were conducted. Recruitment of
patients and controls was carried out during a 12 month period. All patients were
recruited from a psychiatric clinic at the University of Edinburgh Student Health
Service (SHS). Over 90% of students at Edinburgh University are registered at this
practice.
Ethics approval
All of the work carried out in this project was approved by the Lothian Research
Ethics Committee and all participants provided full informed written consent from the
beginning.
Screening assessment
Between July 2002 and July 2003 a total of 234 referrals were made by General
Practitioners (GPs) at the SHS to the psychiatric clinic. These referrals were screened
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by Professor Douglas Blackwood (D.B.) and myself (D.S.) during a standard clinical
assessment interview. At this point the inclusion and exclusion criteria were applied.
Inclusion and exclusion criteria
The main inclusion criterion was a current episode of DSM-IV major depressive
disorder (MDD) and at least one previous DSM-IV major depressive episode (MDE),
with onset of illness before age 22. This age limit was set for two reasons. Firstly,
previous work suggests that this age threshold defines a strongly genetic sub-type of
depressive disorder. Secondly, this study chose to assess bipolar spectrum disorders
in young patients with an early-onset of depression and a history of recurrent
depression because these factors have been linked to the ultimate development of
bipolar disorder.
Patients were excluded if they had a history of previous head injury, epilepsy
or another medical disorder. From the original 234 referrals to the clinic, 144 were
assessed as ineligible to participate (figure 13). Ninety patients satisfied the inclusion
and exclusion criteria and were asked to take part in the study. Eighty seven agreed
and provided written consent.
Controls
Patients participating in the study were asked to volunteer friends of a similar age,
gender, socioeconomic background and who had no personal history of depression to
act as controls. A total of 33 controls were recruited in this way.
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Figure 13. Outline of study
3 declined
87 subjects were formally assessed within one week. Assessment included: SCID-1
FIGS, BSD criteria, HRSD, CGI, GAF, DAST-20, AUDIT.
14 subjects excluded
"^ ( (diagnosis of DSM-IV BPAD)
73 DSM-IV MDD subjects (46 MDD and 27 BSD) received treatment as usual. All
subjects were assessed monthly by DS.
Between 3 and 6 months after recruitment into study, those subjects who were
assessed as euthymic for a period of at least one week underwent neuropsychological
testing.
10 subjects did not achieve euthymia within
six months of recruitment and did not
undergo neuropsychological testing
63 subjects (42 MDD and 21 BSD) underwent neuropsychological testing
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2.3 Data collection
All subsequent descriptive, diagnostic and experimental data was collected by D.S.
2.3.1 Diagnostic assessments
All patients who agreed to take part underwent formal assessment within one week.
Illness characteristics (including age-at-onset, number of affective episodes, history of
deliberate self-harm, and past suicidal behaviour) were derived from retrospective life
charts constructed from the assessment interview and medical records [167], Social
class was defined according to father's occupation [168]. In addition to the
assessment interview, formal DSM-IV diagnoses were obtained on patients and
controls using the Structured Clinical Interview for DSM-IV (SCID-1) [169], This is
a widely used and validated diagnostic instrument that generates diagnoses according
to DSM-IV. It is a standardised interviewer-led assessment tool and D.S. has been
trained in its use. In addition to the DSM-IV diagnosis, the novel structured
diagnostic criteria for BSD (figure 10) [93] were also applied to all patients. The
definition of 'hyperthymia' was based on the criteria outlined in figure 14 and the
definition of'antidepressant-associated hypomania' was hypomania or mania
diagnosed according to DSM-IV criteria (as outlined in figure 6).
According to the Structured Diagnostic Interview for DSM-IV (SCID-1)
[169], 14 patients had bipolar affective disorder (4 had bipolar I disorder and 10 had
bipolar II disorder). Seventy three patients had recurrent MDD. Twenty four of the
73 MDD patients also satisfied the diagnostic criteria for BSD. Only these 73 patients
(46 MDD and 27 BSD) were assessed further, as below.
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Figure 14. Hyperthymic temperament
At least 4 out of the following 6 habitual traits:
1 cheerful, over-optimistic or exuberant
2 extroverted and people-seeking
3 over-talkative, eloquent and jocular
4 uninhibited, stimulus-seeking and sexually-driven
5 vigorous, full of plans, improvident
6 overconfident, self-assured and boastful
Family history data were obtained using the Family Interview for Genetic Studies
(FIGS) [170], The FIGS is a structured diagnostic instrument that has been developed
by the National Institutes for Mental Health in the United States. It is a validated
instrument that is widely used in psychiatric genetics research [170]. Again, D.S. has
been trained in its use.
Drug and alcohol use during the preceding 12 months were assessed by the
20-item Drug Abuse Screening Test (DAST-20; [171]) and the Alcohol Use Disorders
Identification Test (AUDIT; [172]). The DAST-20 is a well validated [173]
questionnaire where subjects are asked questions about their drug use during the
preceding 12 months. Overall scores (from 0 to 20) are generated allocating the
patient to one of five categories, from 'no drug use' to 'severe level of drug use'.
The AUDIT is a brief structured interview developed by the World Health
Organisation (WHO) that can be incorporated into a psychiatric assessment. It
contains questions about recent alcohol consumption, dependence symptoms, and
alcohol-related symptoms. There are ten stems with each scored between 0-4. An
overall score of 8 or more is considered positive for screening and the maximum
possible score is 40. The AUDIT was recently demonstrated to be a valid tool for the
detection of alcohol use disorders in a student population [174],
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Symptom severity was assessed by the 21-item Hamilton Rating Scale for
Depression, (HRSD) [175] and the Clinical Global Impression of Illness scale (CGI)
[176]. Psychosocial impairment during the preceding 12 months was rated using the
Global Assessment of Functioning scale [177], Further details of all assessment
instruments are included within the Appendix.
All 73 patients in the study received treatment as usual in the psychiatric clinic
and from their GPs. This included both medication and, for a small number of
patients, cognitive and behavioural therapy. All were seen on at least a monthly basis
by D.S. for clinical review.
Between 3 and 6 months after recruitment into the study, those patients who
were assessed as being in clinical remission for at least one month went forward to the
next stage of the study (neuropsychological assessment). Euthymia was defined as a
HRSD score of less than or equal to 8. This threshold is recognised as a measure of
clinical remission in depression [175] and has been widely used as a definition of
euthymia in several neuropsychological studies of this kind [115, 127, 132, 133]. Ten
patients did not achieve clinical remission within six months of recruitment and
therefore did not undergo neuropsychological testing. In total, 63 patients (42 MDD
and 21 BSD) and 33 controls underwent neuropsychological testing.
2.3.2 Neurocognitive testing
All patients and controls were assessed by D.S. using a comprehensive fixed-order
test battery spanning two principal cognitive domains (verbal memory and
attention/executive function). All subjects were assessed at 2pm to control for the
effects of diurnal variation on performance. Tests were administered according to
standard instructions and took approximately 60 minutes to complete. All tests were
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completed using pencil and paper methods. Full details of the neuropsychological
tests are included within the Appendix.
An estimate of premorbid levels of intellectual functioning was obtained by
using a combination of three factors: number of years in education; the National Adult
Reading Test (NART) score [178]; and the block-design sub-test of the Wechsler
Adult Intelligence Scale, revised (WAIS-R) [179]. Although the NART and the block
design sub-test of the WAIS are not formal IQ tests, this combination of factors has
been widely used in neuropsychological studies to compare patient and control
groups. An assessment of handedness was also obtained for subjects and controls
using the Annett Handedness Inventory [180], The instruments used to assess each
neurocognitive domain were as follows:
a) Verbal learning and memory:
California Verbal Learning Test (CVLT)
The California Verbal Learning Test (CVLT) [181] is an auditory verbal memory test
using a 16-item shopping list ('list A') that is read to the subject five times. After
each trial of the list read by the investigator, subjects must repeat back as many items
as they can remember. This produces a score for each of the 5 learning trials (trials 1
to 5) as well as a list A total score (trials 1-5 summed). A second shopping list ('list
ET) is then read to the subjects and they are asked to recall these items. Immediately
after this, subjects are asked to recall the items from list A again (free short delay
recall). Subjects are then prompted to try to recall the items on list A by being
prompted with cues, including 'spices and herbs', 'tools', 'clothing' and 'friut' (cued
short recall 1-4). A non-verbal test then follows lasting 20 minutes (in this battery.
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the WAIS-R, Brixton Spatial Anticipation Test and the Trail-making Test parts A and
B) and free (non-cued) long-delay recall of list A is then re-assessed. This is followed
by a repeat of the 4 cued categories and a test of recognition of list A items
(recogniton hits).
b) Attention and executive function:
Trail-making Test
The Trail-making Test, TMT, consists of two parts, A and B [104]. The TMT-A
requires an individual to draw lines sequentially connecting 25 encircled numbers
distributed on a sheet of paper. As such, TMT-A can be considered a test of attention.
The task requirements are similar in TMT-B except the person must now connect
between numbers and letters alternately and in ascending order (i.e., 1, A, 2, B, 3, C,
etc.). The TMT-B is considered a test of set-shifting ability.
Brixton Spatial Anticipation Test
The Brixton Spatial Anticipation Test (BSAT) [182] is a test of executive function
consisting of a 56 page stimulus book. Each page shows the same basic array of ten
circles set in two rows of five, with each circle numbered from one to ten. On each
page one of the circles is filled in with the colour blue. The position of this filled
circle changes on most presentations from page to page. The subject is shown one
page at a time and asked to predict where the next filled position will be. based on
what they have seen on previous pages. The Brixton test is a concept or 'rule
attainment" test and is very similar to (but shorter than) the more widely known
Wisconsin Card Sorting Test.
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Stroop Colour Word Test
The Stroop Colour Word Test [183] is a test of executive function that involves an
initial 'priming' trial of reading aloud a list of colours written in incongruously
coloured ink (Stroop Colour). This is followed by a second 'colour-word' trial
reading aloud a second list of colour names in incongruous coloured ink but this time
naming the colour of the ink rather than the word (Stroop Colour-Word). The number
of correct responses is calculated as the number of colours correctly identified minus
the number of incorrect responses.
2.4 Statistical Analyses
All statistical analyses were performed by D.S. using the Statistical Package for the
Social Sciences, version 12 [184].
2.4.1 Analyses of descriptive clinical and diagnostic data
Given that most of these data were descriptive and exploratory, only limited statistical
testing was carried out. Where formal analyses were conducted, patient groups
(MDD versus BSD) were compared on baseline demographic and clinical
characteristics using independent /-tests for continuously distributed variables and
with chi-squared tests for categorical data. Two-tailed significance for these analyses
was set at p<0.05. This was considered appropriate given the relatively small number
of comparisons carried out in this section. When a statistically significant finding
emerged on the chi-squared tests, odds ratios were also calculated in order to quantify
the magnitude of difference between groups.
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An additional analysis was conducted on four subject groups (MDD, BSD.
BPAD and controls) for selected clinical variables by using ANOVA with the post
hoc Tukey honestly significant different (HSD) test for continuous data and chi-
squared tests for categorical data.
2.4.2 Analyses of neuropsychological test data
Baseline demographic and clinical characteristics
For continuous variables groups were compared on clinical and demographic
characteristics by using analysis of variance (ANOVA) for comparisons between 3
groups (MOD, BSD and controls) and independent /-tests for comparisons between 2
groups (MDD versus BSD). The chi-squared test was used to compare categorical
variables.
Neuropsychological tests
Performance on neuropsychological tests was compared across the three groups
(MDD, BSD and controls) by means of multivariate analysis of variance (MANOVA).
As many of the neuropsychological tests used in this study are naturally correlated,
this procedure was considered superior to a Bonferroni inequality correction because
the latter would tend to increase type II error. A further MANOVA analysis was
performed with gender as a 'between subjects' factor, and with estimated premorbid
intelligence (NART score), age and HRSD scores as covariates. Diagnostic group
(MDD, BSD or controls) was the main factor. These covariates and the 'between
subjects' factor were included in the analysis because of the possibility that even
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small differences on these variables between groups could contribute to differences
observed on neuropsychological testing.
Where significant main effects were detected on MANOVA. group differences
between MDD patients, BSD patients, and controls were then tested in a one-way
ANOVA, followed by a Tukey honestly significant difference (HSD) post hoc
comparison. A two-tailed significance level was set at p<0.05.
In order to place the observed differences between groups into a more
meaningful context, three further analyses were performed: calculation of effect sizes;
estimation of the proportion of MDD and BSD patients scoring on or below the fifth
percentile of controls; and correlations between test scores that showed statistically
significant group differences and the clinical variables of age at onset and number of
previous depressive episodes.
After Howell [185], estimates of effect size were calculated using the formula:
(gpaticnls-M-controlsV&pooled
The first part of this equation was reversed for tasks where a high score indicates
poorer performance (i.e. Pcontrois-Ppatients) to standardise the scoring schemes across
tasks. The Cohen convention for small and large effect sizes was used: small effect
size as less than or equal to 0.5; medium effect size as greater than 0.5 and less than
0.8; and large effect size as equal to or greater than 0.8 [186].
The proportion of MDD and BSD patients scoring on or below the fifth
percentile was determined by calculating the percentage of patients scoring -1.64
standard deviations from the mean of the control sample.
Correlations between those neuropsychological test scores that showed
statistically significant group differences and clinical variables (that is, age at onset
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and number of previous depressive episodes) were tested for the MDD and BSD
groups separately with Pearson correlations. A two-tailed significance level of
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3.1 Prevalence and validity of BSD criteria in young adults with early-onset
recurrent depression.
3.1.1 Diagnostic composition of patient sample
From the 87 patients who were included in the study, 14 (16.1%) fulfilled DSM-IV
criteria for bipolar affective disorder (4 had bipolar I disorder and 10 had bipolar II
disorder). The remaining 73 patients (83.9%) had DSM-IV recurrent MDD. Twenty
seven of these satisfied the diagnostic criteria for BSD, leaving a group of 46 patients
with recurrent MDD. Figure 15 illustrates the diagnostic composition of this patient
sample (46 MDD. 27 BSD and 14 BPAD). If we accept that a BSD diagnosis in this
relatively young patient group may represent a developing bipolar illness, then 41
(47.1%) of the patients in this consecutively recruited sample might be considered to
have a broadly-defined bipolar disorder.





Figure 16. Frequency of'core' BSD criteria in BSD patients (n=27)
BSD criterion Number (%)
A First degree relative with bipolar disorder 8 29.6
B Antidepressant-associated hypomania 12 44.4
Either A or B present 19 70.4
Both A and B present 1 3.7
Neither A nor B present 8 29.6
Figures 16 and 17 show the relative frequencies of the BSD criteria in the 27 patients
who satisfied this diagnosis. In figure 16, it can be seen that 19 of these patients
(70%) had at least one of the core criteria (that is, either a first degree relative with
bipolar disorder or a past history of antidepressant-associated hypomania). This
leaves the remaining 8 patients (30%) fulfilling the BSD criteria by virtue of having
none of these two core criteria but at least 6 of the 9 secondary criteria outlined in
figure 10. As noted above in the introduction chapter, the two core criteria are given
much greater weight diagnostically because of the strength of the evidence that
suggests these features are more strongly associated with bipolar outcome in recurrent
depression.
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Figure 17 provides a more detailed view of the relative frequencies of each of
the criteria in the BSD patients. Of particular note is the fact that 12 patients (44%)
had a history of antidepressant-associated hypomania and 8 (30%) had at least one
first degree relative with bipolar disorder. Only one patient (3.7%) had psychotic
depression and 7 patients (26%) had atypical depression. All of the patients satisfied
the criteria of age of onset before age 25 because of the inclusion criteria for this
study. Similarly, none of the patients had a history of postpartum depression, again
because this sample were relatively young and were recruited from a student
population. All of the BSD patients reported brief episodes of depression (lasting less
than 3 months) and almost all (96%) had experienced more than 3 episodes.
Figure 17. Frequencies of BSD criteria (n=27)
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3.1.2 Demographic and clinical characteristics of the sample
Demographic characteristics of the sample
Table 1 outlines the demographic characteristics of the patient and control samples.
Of particular note is the young age of this cohort (mean age 22 years), the relatively
homogeneous ethnic composition and the relatively high social class. Although these
characteristics are related to the setting of this study and the inclusion and exclusion
criteria that were used, they may represent study strengths in terms of interpreting the
neurocognitive analyses that follow. It can be seen that all three patient groups and
the control group were closely matched on all of the demographic variables.
Table 1. Demographic characteristics
Characteristic MDD BSD BPAD Controls
n=46 n=27 n=14 n=33
Gender, N (%>):













mean (SD) 21.6(2.20) 22.8 (3.01) 21.7 (2.97) 22.2 (2.29)






























Mean (SD) 16.7(1.56) 17.0(1.73) 16.7 (1.67) 17.3 (1.40)
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Clinical characteristics of the sample
Table 2 contains the information that was gathered on the clinical characteristics of
patients and controls.
Table 2. Clinical characteristics
Characteristic MDD BSD BPAD Controls




depression N (%) 33 (71.7) 22(81.5) 11 (78.6) 12(36.4)
bipolar




mean (SD) 0(0) 12 (44.4) 6 (42.9) ...








N (%>) 4(8.7) 7 (26.0) 1 (7.1) ...
HRSD mean (SD) 26.5 (4.60) 27.3 (4.81) 29.7 (4.58) ...
CGI score mean (SD) 4.1 (0.28) 4.3 (0.53) 4.3 (0.47) ...




N (%) 20 (43.5) 16(59.3) 10(71.4) 0(0)
Previous
suicide attempt N (%>) 6(19.6) 7 (26.0) 4 (28.6) 0(0)
DAST-20 score mean (SD) 0.9 (1.09) 1.3 (1.32) 3.1 (3.39) 1.8 (1.02)
AUDIT score mean (SD) 9.2 (5.65) 12.4 (8.26) 10.9(8.00) 8.5 (6.56)
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Table 2 permits a preliminary analysis of the clinical validity of the BSD criteria
according to the categories suggested by Robins and Guze [166]. A key issue is
whether the BSD group appears to be similar to the BPAD group (and sufficiently
different from the MDD group) on measures of clinical phenomenology, clinical
course, family history and treatment response. The principal findings in this regard
are presented below and are considered in more detail within the discussion chapter.
a) Clinical phenomenology
Across all three patient groups (MDD, BSD and BPAD) there were no significant
differences in terms of severity of the index depressive episode (HRSD and CGI
scores) or levels of psychosocial functioning as measured by GAF scores (table 2).
However, significantly more of the BSD patients reported atypical depression as the
index depressive episode (26.0% in BSD patients compared to 8.7% in MDD
.9
patients; X =3.95, df=l, p<0.05). This is an interesting finding in the light of work
suggesting that atypical depression (which includes symptoms such as extreme
fatigue, hypersomnia, hyperphagia and sensitivity to rejection) may be more common
in bipolar depression than unipolar depression [59, 187], It must be acknowledged,
however, that only 1 of the 14 BPAD patients (7%) had an atypical index depressive
episode.
There was a non-significant trend towards higher rates of deliberate self-
harm and suicidal behaviour in both bipolar groups compared to the MDD group
(table 2). 71% of the BPAD patients had harmed themselves in some way in the past
compared to 59% in the BSD group and 44% in the MDD group. Similarly, rates of
at least one previous suicide attempt were 29% in the BPAD group, 26% in the BSD
group and 20% in the MDD group.
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Levels of reported drug use in this study were lower than anticipated,
probably as a result of under-reporting. Other reasons for this are considered more
fully within the discussion chapter. Although the maximum possible score on the
DAST-20 questionnaire was 20, the mean reported scores for all patient groups were
between only 1 and 3. There were no differences between MDD patients, BSD
patients and controls on mean DAST-20 scores but BPAD patients had significantly
higher scores than the three other groups (F=9.41, df=3, p<0.01).
Using the recommended threshold of 8 on the AUDIT screening
questionnaire, 66% of all patients and 53% of controls screened positive for a
possible alcohol use disorder. This difference was non-significant and there were no
differences in positive screening rates between the MDD, BSD and BPAD groups.
The mean AUDIT score was significantly higher in the BSD group compared to the
MDD group (t=-2.06, df=71, p<0.04) and there was no difference between the BSD
group and BPAD group on this measure.
Overall, as with drug use, levels of alcohol use during the preceding 12
months were lower than anticipated in all groups. This relatively low level of alcohol
consumption may again be a consequence of under-reporting but, if we accept it as a
true reflection of alcohol use in this sample, it may add strength to the neurocognitive
findings presented in the next section, as heavy alcohol use has an obvious potential
to confound neuropsychological studies.
b) Clinical course
There were also no significant differences between the three patient groups in terms
of age at onset of depression or number of previous depressive episodes (table 2).
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c) Family history
In terms of family history, there were very similar rates of at least one first degree
relative with depression across all three patient groups (71.7% for MDD, 81.5% for
BSD and 78.6% for BPAD). When the patient group as a whole was compared to
controls, perhaps unsurprisingly, there was a significantly greater proportion of
patients with a first degree relative with depression (X2=13.8, df=l, p<0.001). A
direct comparison between MDD patients and BSD patients on family history of
depression was non-significant (table 2).
There were similar rates of having a first degree relative with bipolar
disorder within the BSD and BPAD groups and no bipolar family history within the
MDD or control groups. Rates of a bipolar family history in the MDD and BSD
groups were significantly different (X2=15.31, df=l, p<0.001), although clearly this
may be related to the fact that having a first degree relative with bipolar disorder was
one of the core diagnostic features of BSD. Having said this, it is still of interest that
similar rates of family history for bipolar disorder were found in the BSD and BPAD
probands (29.6% versus 21.4% respectively).
d) Treatment response
The only data that was collected that can be used to make an assessment of treatment
response was the rate of antidepressant-associated hypomania. As with family history
for bipolar disorder, this criterion was also a core diagnostic feature of BSD.
Unsurprisingly, this too showed significantly different rates between the MDD and
BSD groups (44.4% in the BSD group versus 0% in the MDD group; X2=24.47, df=l,
p<0.001). Rates of antidepressant-associated hypomania were very similar in the
BSD and BPAD groups (44.4% and 42.9% respectively).
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3.2 Neurocognitive function in young adults with MDD and BSD
The findings of the neuropsychological study are reported in this section. As noted in
the methods chapter, 42 MDD patients and 21 BSD patients achieved euthymia
(defined as at least one month of clinical remission with a score of less than 8 on the
HRSD). These patients underwent neurocognitive testing along with 33 euthymic
controls with no past history of mood disorder. The neuropsychological battery tested
two principal cognitive domains: verbal memory and attention/executive function.
3.2.1 Baseline demographic and clinical characteristics compared
The three diagnostic groups were well matched in terms of age, gender distribution,
handedness and current depressive symptoms (table 3). The estimate of premorbid
intellectual function (that is, a combination ofNART IQ score, block design score on
the WAIS and number of years in education) was also similar across the three groups.
There were no differences in these variables when the three groups were compared
using ANOVA and a Tukey post hoc analysis did not identify differences between
MDD patients versus BSD patients, BSD patients versus controls or MDD patients
versus controls.
Table 3 also contains clinical data relating to the MDD and BSD groups,
including mean age at onset of depression, mean number of depressive episodes and
class of medication at the time of neuropsychological testing. A direct comparison
between the MDD and BSD groups did not find any significant differences between
them on these clinical variables, although the mean number of depressive episodes
was approaching significance (BSD = 4.7, MDD = 4.0; p<0.06).
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A chi-squared comparison of medication status in the MDD and BSD groups
was also non-significant but this is potentially a complex area. Because of this, a
more detailed table of medications being taken by patients in both groups is included
in table 4. Inspection of this table reveals that more MDD patients were taking
antidepressants alone compared to BSD patients (MDD = 83% versus BSD = 62%)
and that a greater proportion of BSD patients were taking mood stabilisers alone
(MDD = 10% versus BSD = 19%). BSD patients were also more frequently taking a
mood stabiliser plus an antidepressant (MDD = 5% versus BSD = 19%). It might be
argued that these differences (although non-significant on a straightforward chi-
squared comparison) may represent potential confounding factors. In particular, the
fact that more BSD patients were on combination therapy (a mood stabiliser plus an
antidepressant) may be an important confound. This issue is considered in more
detail within the discussion chapter.
The relative frequencies of each of the BSD criteria for the 21 BSD patients is
presented in table 5. It is may be the case that the BSD criteria are not necessarily
detecting bipolarity but rather are simply selecting out a more severe unipolar
depressive sub-group, for example, young patients who have had psychotic episodes.
If this were the case, then differences in performance on neuropsychological testing
might simply be a consequence of a more severe depressive disorder in the BSD
group. However, the figures in table 5 do not support this. None of the BSD patients
who underwent neuropsychological testing had psychotic depression. This issue is
also addressed in more detail within the discussion chapter.
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Currentmedications: Antidepressantsonly,(%) Moodstabilisersonly,(%) Both,n(%) Neither,n(%)
35(83) 4(10) 2(5) 1(2)
13(62) 4(19) 4(19) 0(0)
—
X2=3.54(df=l) X2=1.15(df=l) X2=3.32(df1) X2=0.51(df=l)





Table4.Detailsofclass sndd i yosespsychotropicmedic ti nbe gtakenp tie tgr upthi fneuro ychol gica testing. PsychotropiclassMDDgroup (n=42)BSDgroup (n=21) Antidepressantsalone35patients(83.3%): 22patients(52.3%)weretaki gSSRIs:11oncitalop am,4 paroxetine,7onfluoxeti .SSRIequivalentdos s:9patients 20mg,10on4 gand360mg. 6patients(14.3%)weretaki gnSNR1( llvenlafaxine):2o 150mg,3on225 gand30 5patients(11.9%)weretaki gNaSSA( llmirtazepine):2on30mg an3o45mg. 2patients(4.8%)weretaki gTCA(bo hamitriptyll ne):bo h 200mg13patients(61.9%): 5patients(23.8%)weretaki gSSRIs:3oncitalopram, fluoxetine.SSRIequivalentdos s:2pat entsn0mg,3 40mg. 6patients(28.6%)weretaki gnSNR1( llvenl faxine):3o 150mg,2on25 gand30 1patient(4.8%)wastaki gNaSSA(mirtazepi et30mg. 1patienttaki gRIMA(moclobemide)450mg. Moodstabilisersalon4patients(9.5%): onepatientcarb maz pi e800 g,onsodiumvalpro telgand 2onsodiumvalproate800mg4patients(19.0%): onepatientlamotriginelOOmg,2patientss d um valproate600mgand1p tientosodiuv lproate800mg. Bothantidepressantsndmoo stabilisers2patients(4.8%): onesodiumvalproate600mgplusar xetine20mg,ons dium valproate800mgplusaroxetine2 mg4patients(19.0%): 2patientsweretaki gmirtazepi e30mgpluslamotrigine lOOmgand2patientsweretaki gvenlafaxine150mplus sodiumvalproate800mg. Nomedication1patient(2.4%)None
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Table 5. Relative frequencies of each BSD criterion for patients satisfying BSD
diagnostic criteria (n=21).
BSD criterion n (%)
A At least one major depressive episode 21 (100)
B No spontaneous DSM-IV hypomanic or manic episodes 21 (100)
C Either of the following, plus at least two items from criterion D, or
both of the following plus one item from criterion D:
CI First degree relative with bipolar disorder
C2 Antidepressant-induced mania or hypomania
6(28.6)
1 1 (52.4)
D If no items from criterion C are present, at least six of:
D1 Hyperthymic personality (at baseline, non-depressed state)
D2 Recurrent major depressive episodes (> 3)
D3 Brief major depressive episodes (< 3 months)
D4 Atypical depressive symptoms (DSM-IV criteria)
D5 Psychotic major depressive episodes
D6 Early age of onset of major depressive episode (< age 25)
D7 Postpartum depression
D8 Antidepressant 'wear-off (acute but not prophylactic response)











3.2.2 Neurocognitive function results
fable 6 contains the mean scores and standard deviations for each of the
neuropsycholological tests that were administered to the three groups (MDD. BSD
and controls). A mulitvariate analysis of variance (MANOVA) comparing these
groups found significant differences between them within several of the CVLT
categories, for the Stroop Colour Word test and for both parts of the Trail-making test
(A and B) (table 6). With respect to the CVLT, the significant differences were
identified in trials 1 to 5, trials 1 to 5 total free recall, short delay free recall, cued
recall (C1.1, CI .4, C2.1, C2.4), long delay free recall and recognition. The
differences between groups were non-significant for the Stroop Colour test and the
Brixton Spatial Anticipation Test. From this analysis, MDD patients and BSD
patients differed from controls on many of the tests of verbal learning and memory as
well as on two of the three tests of attention and executive function. Furthermore,
from inspection of the mean scores within table 6, it can be seen that the BSD patients
consistently performed less well than the MDD patients on all of the tests.
Given that performance on these tests may be influenced by factors such as
gender, age, premorbid IQ and current levels of depressive symptoms, these variables
should be taken into account where possible (even though from, table 3, the three
groups are reasonably well matched on these variables). To address this, another
MANOVA was calculated with gender as a 'between subjects' factor and with age,
premorbid IQ (NART score) and depressive symptoms (HRSD score) entered as
covariates (table 7). It can be seen that this further MANOVA does not alter the main
findings presented in table 6. All of the tests that were significantly different between
groups from table 6 remain significantly different in table 7. This finding suggests
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that the differences in performance were not confounded by subtle differences
between groups on gender ratio, age, premorbid IQ or low levels of depressive
symptoms at the time of testing.
In order to identify where the differences between groups lay. an ANOVA,
with a post hoc Tukey HSD test, was carried out for those variables where a
significant main effect was identified by MANOVA. This allowed a comparison to
be made between MDD patients and BSD patients, between BSD patients and
controls and between MDD patients and controls. These findings are presented in
table 8.
i) MDD versus BSD:
On the CVLT, statistical differences between the MDD group and the BSD group
emerged for trials 1 to 5 total free recall (p<0.05), short delay recall (p<0.009), cued
recall (C 1.1, CI.4, C2.1, C2.4; p<0.05 to p<0.02) and recognition hits (p<0.02).
For tests of attention and executive function, the only significant difference
between the MDD and BSD groups was in the Trail-making test, part B (p<0.03).
ii) BSD versus controls:
BSD patients performed significantly less well than controls on all of the
neuropsychological test scores outlined in table 8. with significance levels ranging
from 0.001 to 0.04.
Hi) MDD versus controls:
Differences were less pronounced when MDD patients were compared to controls.
Although the mean scores for MDD patients were lower than controls for most of the
103
tests, only trials 4 and 5 of the CVLT (p<0.05) and Trail-making A (p<0.001) and B
(p<0.005) were statistically significant (table 8).
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Although these differences identified between the three groups are of
considerable interest, it should be acknowledged that they are still quite subtle and
that many of the scores for the patient groups may fall within the normal range.
Furthermore, these differences will not necessarily be associated with significant
cognitive or functional impairment. In order to quantify the degree of difference in
performance between the groups, effect sizes have been calculated and are presented
in table 9. In table 10, the percentage of MDD and BSD patients falling below the 5th
percentile of controls (for those scores that were identified as demonstrating a
significant main effect from the MANOVA) are also presented. This latter measure
quantifies how many of the MDD and BSD patients performed at a very low level
relative to controls.
In terms of effect sizes, Cohen's convention suggests that less than 0.5 should
be considered small, between 0.5 and 0.7 should be considered medium and more
than 0.8 should be thought of as large [186], When the MDD and BSD groups were
compared to controls, most of the effect sizes were in the medium to large range
(table 9). For example, for the CVLT category of trials 1 to 5 total free recall, the
effect size for BSD patients versus controls was 1.04 and for MDD patients versus
controls it was 0.57. Similarly, for the Trail-making test part B, the effect size for
BSD patients versus controls was 1.45 and for MDD patients versus controls it was
0.76. These findings suggest that the differences between the two patient groups and
controls were notable and it is of interest that the effect sizes for BSD patients versus
controls were consistently higher than the effect sizes for MDD patients versus
controls.
In terms of the comparison between the MDD group and the BSD group, most
of the effect sizes lay within the medium range (eg, CVLT trials 1 to 5 total free recall
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= 0.56. CVLT short delay recall = 0.71, CVLT recognition hits 0.63 and Trail-making
part B = 0.61). This suggests that although the differences between the BSD group
and the MDD group were smaller than between either of these groups and controls,
they were still important.
This is supported by the data in table 10 showing the percentage of MDD and
BSD patients scoring below the 5th percentile of controls. It is notable that 38% of
BSD patients and 17% of MDD patients were below the 5lh percentile of controls for
the CVLT trails 1 to 5 total free recall and that the corresponding figures for the
CVLT short delay recall were 33% of BSD patients and 14% of MDD patients. These
findings were even more pronounced for the tests of attention and executive function.
Forty seven percent of BSD patients (and 28% of MDD patients) were below the 5th
percentile for the Stroop Colour Word test. Similarly, 71% of BSD patients and 45%
of MDD patients were below the 5lh percentile for the Trail-making test part A. The
figures for Trail-making part B were 52% of BSD patients and 21% of MDD patients.
Ill
I able 9. Effect sizes for neuropsychological tests demonstrating significant main
effect from MANOVA.
Neuropsychological domain and Effect size: Effect size: Effect size:
measure
MDD v BSD BSDv MDD v
Controls Controls
CVLT:
Trial 1 0.41 0.64 0.30
Trial 2 0.37 0.96 0.53
Trial 3 0.53 0.96 0.40
Trial 4 0.33 0.80 0.67
Trial 5 0.08 0.86 0.70
Trials 1 to 5 total recall 0.56 1.04 0.57
Short delay recall 0.71 0.90 0.15
Cl.l 0.84 0.78 0.12
CI.4 0.74 0.70 0
Long delay recall 0.37 0.81 0.45
C2.1 0.77 0.68 0.13
C2.4 0.49 0.61 0.19
Recognition hits 0.63 0.82 0.17
Attention/executive function:
Stroop colour-word 0.45 0.88 0.53
Trail-making Part A (s) 0.39 1.48 1.01
Trail-making Part B (s) 0.61 1.45 0.76
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Table 10. Percentage of MDD and BSD patients scoring below the 5th percentile
of controls (for tests demonstrating significant main effect from MANOVA ).
Neuropsychological test MDD patients below the
5th percentile of controls
n (%)
BSD patients below the
5th percentile of controls
n (%)
CVLT:
Trial 1 1 (2.4) 3 (14.3)
Trial 2 13 (31.0) 10 (47.6)
Trial 3 5 (11.9) 5 (23.8)
Trial 4 6 (14.3) 8 (38.1)
Trial 5 12 (28.6) 8 (38.1)
Trials 1 to 5 total recall 7 (16.7) 8 (38.1)
Short delay recall 6 (14.3) 7 (33.3)
C1.1 7 (16.7) 8 (38.1)
CI.4 1 (2.4) 6 (28.6)
Long delay recall 8 (19.0) 7 (33.3)
C2.1 6 (14.3) 8 (38.1)
C2.4 1 (2.4) 4 (19.0)




Trail-making Part A (s)








3.2.3 Correlations between illness characteristics and neurocognitive
performance
Tables 11 and 12 present the findings of a correlation analysis between illness
characteristics (age at illness onset and number of previous depressive episodes) and
performance on neuropsychological testing. No significant correlation was detected
between number of depressive episodes and cognitive performance for either of the
two patient groups.
However, age at onset was negatively correlated with some of the CVLT test
scores for both the MDD patients and the BSD patients. In the MDD group (table
11), there was a significant negative correlation between age at onset and CVLT trial
3 (p<0.05), trial 4 (p<0.007) and trials 1 to 5 total free recall (p<0.05). For the BSD
group (table 12) a significant negative correlation between age at onset and
performance was found for two of the cued recall scores (CI .4, p<0.02 and C2.4,
p<0.03). It is interesting that none of the attention or executive function tests showed
any correlation with age at onset or number of depressive episodes for either of the
patient groups.
To summarize, these findings suggest that early age at onset in MDD, and, to a
lesser extent, in BSD, is associated with poorer performance on certain tests of verbal
memory but not associated with impaired attentional or executive function. Further,
there was no association for either patient group between verbal memory or
attention/executive function performance and number of previous depressive
episodes. One conclusion from this might be that verbal memory impairment in
MDD and BSD is more closely related to early age at onset (and possibly, by
extension, either greater genetic loading for affective disorder or the experience of
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more adverse events in childhood) rather than simply being a consequence of
recurrent episodes of illness. This finding is considered in more detail within the
discussion section.
Table 11. Correlations between illness characteristics and neuropsychological
performance (MDD patients, n=46).
Neuropsychological test Age at onset Number of depressive
episodes
Pearson's r, P Pearson's r, P
CVLT:
Trial 1 -0.16, 0.31 0, 1
Trial 2 -0.12, 0.45 -0.10, 0.54
Trial 3 -0.31, 0.05 0.03, 0.87
Trial 4 -0.41, 0.007 0.17, 0.29
Trial 5 -0.18, 0.25 -0.12, 0.46
Trials 1 to 5 total recall -0.31, 0.05 -0.04," 0.82
Short delay recall -0.22, 0.16 0.01, 0.96
Cl.l 0.14, 0.37 -0.1 1, 0.51
CI .4 -0.09, 0.57 -0.14, 0.39
Long delay recall -0.16, 0.33 0.01, 0.93
C2.1 0.11, 0.49 -0.14, 0.39
C2.4 -0.17, 0.20 -0.10, 0.45
Recognition hits 0.05, 0.73 -0.18, 0.25
Attention and executive
function:
Stroop colour-word -0.04, 0.80 -0.14, 0.38
Trail-making Part A (s) 0.03, 0.87 0.01, 0.97
Trail-making Part B (s) 0.03, 0.87 0.05, 0.77
Table 12. Correlations between illness characteristics and neuropsychological
performance (BSD patients, n=21).
Neuropsychological test Age at onset Number of depressive
episodes
Pearson's r, P Pearson's r, P
CVLT:
Trial 1 -0.03, 0.89 0.83, 0.72
Trial 2 0.03, 0.90 0.07, 0.78
Trial 3 -0.15, 0.52 0.17, 0.45
Trial 4 -0.11, 0.64 0.02, 0.92
Trial 5 -0.34, 0.13 0.25, 0.28
Trials 1 to 5 total recall -0.18, 0.44 0.11, 0.64
Short delay recall -0.33, 0.14 0.35, 0.12
Cl.l -0.12, 0.60 0.09. 0.69
CI .4 -0.49, 0.02 0.40, 0.07
Long delay recall -0.34, 0.13 0.30, 0.20
C2.1 -0.06, 0.80 0.04, 0.87
C2.4 -0.47, 0.03 0.24, 0.29
Recognition hits -0.17, 0.47 0.29, 0.20
Attention and executive
function:
Stroop colour-word 0.05, 0.85 -0.04, 0.88
Trail-making Part A (s) 0.14, 0.56 -0.17, 0.47
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4.1 Diagnostic and clinical findings
4.1.1 Discussion of diagnostic and clinical findings
In the introduction to this thesis I have presented data that suggests that an onset of
major depression in adolescence or young adulthood, that is followed by recurrence
of depression, may represent a precursor for the development of bipolar disorder.
Unlike unipolar depression, which tends to begin later in life, bipolar disorders
characteristically begin (usually with a depressive episode) in adolescence or early
adulthood. It is also the case that there is often a long delay between the first
presentation of a bipolar disorder and diagnosis. Earlier detection of bipolar disorders
therefore has the potential to impact significantly on future illness course.
1 have reviewed evidence to suggest that ICD-10 and DSM-IV (by virtue of
having broad criteria for depression but relatively narrow criteria for bipolar disorder)
have tended to over-diagnose recurrent depressive disorder at the expense of bipolar
disorders. This observation has led to the suggestion of modifications to the DSM-IV
criteria, such as including behavioural activation as a stem criterion and reducing the
minimum duration threshold for hypomanic symptoms from 4 to 2 days [73], It has
also led to the suggestion of structured diagnostic criteria for bipolar spectrum
disorder (BSD) [93] (figure 10) that highlight the importance of factors such as
having a first degree family history of bipolar disorder or a personal history of
antidepressant-associated hypomania.
When one considers that young adults with early-onset, recurrent depression
may be at high risk of ultimately developing a bipolar disorder throughout their
lifetime, it is perhaps not surprising that many of the patients in this study satisfied
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the BSD criteria for a 'softer', or more broadly-defined, bipolar disorder. Out of the
73 patients with recurrent MDD, 27 (37%) also fulfilled the BSD criteria. Nineteen
of these 27 patients (70%) had at least one of the core BSD criteria (either a positive
first degree family history of bipolar disorder or a personal history of antidepressant-
associated hypomania). Including those 14 patients from the cohort with BPAD
means that 41 (47%) of these consecutively-recruited patients could be considered to
have a broadly defined bipolar illness. This figure is in line with the 1:1 ratio of
broadly-defined bipolar disorder to depression identified in the Zurich study [75, 188]
and in a number of other studies [77, 79, 189, 190], In clinical practice, this would
suggest that young adults with early-onset, recurrent depression should be carefully
assessed for the possibility that they might have an early bipolar disorder.
Diagnosing a possible bipolar disorder rather than a straightforward unipolar
disorder may have important implications for the pharmacological treatment choices
that are made. It appears to be the case that a significant proportion of bipolar
patients (around 20%) may be ill-served by recurrent courses of antidepressant
medication that can cause anti-depressant associated hypomania, mixed affective
states and a rapid-cycling course of illness [86].
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4.1.2 Limitations of diagnostic findings
Although the first main finding in this thesis was the relatively high number of young
patients who satisfied the criteria for BSD, the relevance and importance of this
finding depends on a number of factors. It must be acknowledged that the criteria for
BSD are not yet fully validated in large patient samples. There is good evidence that
the two core criteria in BSD are associated with bipolar disorder (that is, having
recurrent depression with either a first degree relative with bipolar disorder or a
personal history of antidepressant-associated hypomania). Both of these factors have
been identified as predicting bipolar outcome in several longitudinal studies of
depressed patients (85, 86, 88, 89, 188], However, the evidence for the 9 additional
clinical features also outlined in the BSD criteria as being strongly associated with
bipolar outcome is somewhat less convincing. Indeed, the threshold of 6 out of these
9 features required to be present in the absence of the 2 core criteria appears to have
been an arbitrary choice with no clear justification. A further criticism might be that
the assessment of these 'soft bipolar' features at a single interview and without
corroborative information from family members is unreliable. Having said this, as
noted above, the majority of BSD patients in this study (70%) were diagnosed as
having BSD on the basis of at least one of the core diagnostic features rather than on
the basis of the secondary (and probably less reliable) criteria, adding strength to the
assertion that they may have a bipolar-related illness.
At the time of writing there has been only one published study which has
directly assessed the validity of the BSD criteria against DSM-IV diagnosed BPAD
patients. Ghaemi and colleagues compared 36 patients with DSM-IV bipolar I or II
disorder to 37 unipolar depressives [92], The five most powerful predictors of bipolar
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disorder were brief major depressive episodes, early age at onset, anti-depressant
associated hypomania, postpartum depression and atypical depressive symptoms.
Perhaps surprisingly, family history for bipolar disorder did not emerge in this study
as a major predictor for bipolar disorder.
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4.1.3 Can the BSD criteria be validated in this sample according to clinical
parameters?
Because of the small numbers of BPAD patients (n=14) relative to MDD (n=46) and
BSD (n=27) patients assessed at the beginning of the current study, it is difficult to
draw firm conclusions about the validity of the BSD criteria based on comparisons of
clinical features between the three diagnostic groups. Despite this, some of the
clinical data collected permit a preliminary consideration of the validity of the BSD
criteria by assessing similarities and differences between these groups. As noted in
the introduction, the classic Robins and Guze criteria for validating the diagnosis of a
psychiatric disorder include: i) clinical phenomenology; ii) clinical course; iii) family
history; and iv) treatment response [166],
In terms of clinical phenomenology, it might be argued that the higher rate of
atypical depression in the BSD group compared to the MDD group (26% versus 9%)
is suggestive of a bipolar-type disorder because atypical depression appears to be
more common in bipolar depressive episodes (and especially those with bipolar II
disorder) compared to unipolar episodes [59, 60, 92], It has also been shown that
patients with atypical depression have relatively high rates of soft bipolar features
[1 87], However, it is also the case that only one of the 14 BPAD patients in this data
set (7%) had atypical depression. Clearly this analysis would have benefited from
comparison with a larger number of DSM-IV BPAD patients.
The clinical course of the three diagnostic groups was very similar in terms of
age at onset of depression and number of previous depressive episodes. From what is
already known about the natural history of unipolar depression and bipolar disorder, it
might have been expected that the BPAD and BSD groups would have had an earlier
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age at onset and more depressive episodes. Although the BSD patients were no
different from the MDD patients on number of previous depressive episodes, this may
have been because only a relatively brief period had passed (approximately 7 years)
since their first episode. A longer period of follow up might be expected to show
more episodes for the BSD and BPAD groups relative to the MDD group.
Similarly, the BSD patients did not differ significantly from the MDD patients
(and were not necessarily more closely similar to the BPAD patients) on clinical
course features such as a history of deliberate self-harm, previous suicide attempts,
DAST-20 scores or AUDIT scores. It may be of interest that for rates of a history of
deliberate self-harm and in terms of raw DAST-20 scores the BSD patients appeared
to occupy an intermediate position between the MDD patients and BPAD patients
(table 2). It would be difficult to argue, however, that this represented good evidence
for the validity of the BSD criteria based on clinical course features, especially when
a direct comparison between BSD patients and MDD patients on these variables does
not identify any significant differences (table 3).
Any attempt to validate the BSD criteria on the basis of family history is
likely to be difficult because family history for bipolar disorder was one of the core
criteria for BSD. Nonetheless, it is interesting that the rate of bipolar family history
was similar in the BSD and BPAD groups (30% versus 21% respectively). Although
the rates of having at least one first degree relative with depression were 72% in the
MDD group, 82% in the BSD group and 79% in the BPAD group, these differences
were not statistically significant. It might have been expected that the BSD criteria
would identify higher rates of depression in the BSD and BPAD groups but this is not
the case. Overall, family history in this data set does not provide any substantial
support for the validity of the BSD criteria.
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Il is also difficult to apply Robins and Guzes' final validity criterion,
treatment response, to these data because this was not formally assessed apart from
the information that was gathered on a past history of antidepressant-associated
hypomania. As with having at least one first degree relative with bipolar disorder,
this variable was a core feature of the BSD criteria. As a result, it probably should
not be used to formally assess the validity of the BSD criteria. From a purely clinical
perspective, however, it is of interest that 44% of BSD patients and 43% of BPAD
patients had experienced antidepressant-associated hypomania.
Overall, the clinical data permit only a cautious assessment of the validity of
the BSD criteria. It would appear that applying the Robins and Guze criteria for the
validity of psychiatric diagnoses does not provide convincing evidence that the BSD
criteria are valid in identifying bipolar disorder in this data set. This is the case even
though some of the findings (such as the rates of atypical depression, the levels of
family history for bipolar disorder and the rates of antidepressant-associated
hypomania) might suggest that the BSD criteria may have some clinical usefulness.
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4.1.4 Implications for the design of future studies assessing the validity of the
BSD criteria
It is clear from the above that there were limitations to the degree to which clinical
features could be used in this data set to make judgements about the validity of the
BSD criteria. Not enough BPAD patients were available to make reliable
comparisons between the groups, one of the validity criteria (treatment response) was
not systematically assessed in sufficient detail and the group itself (mostly students)
were highly selected in terms of social, economic and educational status. Having said
this, there are very few studies of this kind published to date and these data represent
one of the first attempts to report the clinical features of possible 'soft bipolar'
disorders in a consecutively recruited cohort of young adults with recurrent MDD.
Ideally, future studies that are designed to assess the validity of the BSD
criteria should identify large, socially and economically diverse cohorts of
adolescents and young adults presenting with a first episode of major depression.
They should be followed prospectively over a number of years (probably at least 20,
so that they pass through the median age of onset of mania) and assessed on a regular
basis according ICD-10, DSM-IV and BSD criteria. Information about clinical
phenomenology, clinical course, family history and treatment response should be
collected so that at the end of the study the Robins and Guze criteria can be applied.
This kind of study would be likely to generate a great deal of useful
information about the correct diagnosis and clinical course of bipolar spectrum
disorders but would obviously also be logistically difficult and extremely expensive.
Nonetheless, this is exactly the kind of approach that was taken with the Zurich study
which is now producing a great deal of useful information about the natural history of
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mood disorders. A study of this length should also have the capacity to respond to
changes in diagnostic practices. For example, it may be that subsequent versions of
ICD and DSM will incorporate the idea that mood disorders should be diagnosed
along a continuum rather than categorically.
A less ambitious, but perhaps more achievable, assessment of the validity of
the BSD criteria could be achieved by applying the criteria to socially and
demographically matched samples of patients with major depressive disorder and
bipolar disorder. As with the preliminary study above by Ghaemi and colleagues, this
approach may be able to identify which of the BSD criteria are most strongly
associated with bipolar disorder rather than with major depressive disorder.
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4.2 Neurocognitive findings
4.2.1 Discussion of neurocognitive findings
The aim of the neuropsychological study in this thesis was to compare neurocognitive
function in the euthymic state between young adults with MDD, young adults with
BSD and well matched euthymic controls. The main hypothesis being tested was that
there would be differences between both of the patient groups and controls on tests of
prefrontal and hippocampal function. Based on previous work of this kind with
euthymic BPAD patients, it was also hypothesised that the BSD group might have a
different pattern of cognitive performance than the MDD group.
From the neuropsychological literature of mood disorders, it appears to be the
case that the patterns of neurocognitive impairment in euthymic BPAD patients,
especially in the domains of attention/executive function and declarative memory, are
similar to (but more severe than) those impairments that are seen in euthymic MDD
patients. However, it should be remembered that at the time of writing there are no
good quality studies published that directly compare euthymic bipolar patients to well
matched euthymic unipolar patients. The greater degree of attention/executive
function and declarative memory impairment in bipolar disorder relative to unipolar
disorder may be a reflection of a number of factors. It is possible that it is a
consequence of more severe affective episodes, more frequent episodes or greater life¬
long sub-syndromal psychopathology in bipolar patients. It may also be a result of a
greater medication load or higher rates of drug and alcohol misuse in bipolar patients.
Having said this, there is now evidence to suggest that although these factors do exert
an influence on cognitive performance, they may not be as important as high genetic
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loading for mood disorder. As discussed in the introduction, several studies have now
suggested that impaired attention/executive function and/or declarative memory
function in recovered patients with mood disorders may represent endophenotypic
abnormalities, or intermediate phenotypes, that are closely linked to genetic risk.
These suggestions come from twin and family studies [136, 137], retrospective and
prospective analyses of premorbid neurodevelopmental functioning [139-141] and the
assessment of unaffected biological relatives [142-144],
If one accepts that attentional abnormalities, executive dysfunction and/or
declarative memory disturbances are indeed neurocognitive markers of a bipolar
diathesis, then it would follow that young adult patients with a soft bipolar disorder
might exhibit these abnormalities to a greater extent than MDD young adults or
controls. Furthermore, if the suggested criteria for BSD used in this study are indeed
defining a bona fide bipolar sub-group, it would be expected that there would be a
gradation of deficit whereby BSD patients were most impaired, followed by MDD
patients, followed by controls - this is in fact the pattern of neurocognitive impairment
that has emerged in the present study.
To summarize the neurocognitive findings, there were significant differences
between the BSD and MDD groups on several components of the CVLT (trials 1 to 5
total free recall, short delay recall, cued recall and recognition hits) and on the Trail-
making test part B, suggesting that the BSD group were more impaired on both verbal
memory and on one of the tests of executive function. Although the MDD group was
more impaired than controls on some of the CVLT components (learning trials 3 and
4 and trials 1 to 5 total free recall) and on both part A and part B of the Trail-making
test, the BSD group were much more impaired than controls on all of the CVLT
components, on the Stroop Colour Word Test and on both parts of the Trail-making
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test. These findings suggest that the range and degree of prefrontal and hippocampal
impairment in euthymic BSD patients was greater than euthymic MDD patients and
considerably greater than in controls. This pattern of both prefrontal and hippocampal
impairment is consistent with a number of previous neuropsychological studies of
bipolar disorder [101, 131-134, 191]. It is notable that this young euthymic patient
group were selected for early age at onset and recurrence and that almost all had
strong family histories of mood disorder. In this context, the finding of a combined
deficit in prefrontal and hippocampal function supports the view that these
impairments may represent endophenotypic traits that are markers of genetic
vulnerability to bipolar disorder.
Given the age of this patient sample and the relatively high degree of matching
in terms of baseline characteristics and previous illness course, these findings support
the assertion that the BSD criteria are detecting a sub-group of young mood
disordered patients with a strong bipolar diathesis which is a consequence of a higher
genetic loading for mood disorder. Indirectly, these findings might also lend support
to the validity of the BSD criteria. It could be argued, however, that as long as the
exact pathophysiology of mood disorders remains unknown, diagnostic validity
should only be assessed using the four clinical categories described by Robins and
Guze.
It could be that the BSD criteria were simply detecting young patients with
more severe unipolar depression (for example, with a past history of psychosis or
more frequent depressive episodes) rather than necessarily picking up on a 'soft
bipolar' phenotype. However, this does not appear to have been the case. None of
the BSD patients in this study who underwent neuropsychological testing had a past
history of psychotic symptoms and the BSD and MDD groups were well matched in
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terms of age at onset, number of depressive episodes and severity of the most recent
episode.
4.2.2 Limitations of neurcognitive findings
Although there were methodological strengths to this study, such as the use of
objective structured diagnostic instruments and a high degree of matching between
BSD patients, MDD patients and controls, there were also potential limitations that
are addressed in more detail under the categories below.
a) How well were the groups matched on baseline characteristics?
Overall, compared to many previous studies of this kind, the patients and controls in
this study were relatively homogeneous in terms of age, gender distribution, social
class, educational status and estimates of premorbid IQ. There were no differences
between the three groups on any of these variables. The two patient groups were also
reasonably well matched in terms of levels of current symptoms and other clinical
variables such as age at onset of depression, number of previous depressive episodes
and current medications. Despite this relatively high degree of matching for baseline
characteristics, the MANOVA presented in table 7, which compares BSD, MDD and
controls on neuropsychological test scores, included an additional analysis of gender
as a 'between subjects' factor and age, premorbid IQ (NART IQ score) and HRSD
score entered as covariates. As noted in the results section, this additional analysis
did not change any of the significant findings between groups.
A major limitation in the baseline data was the lack of an objective rating for
current manic symptoms, such as the Young Mania Rating Scale (YMRS) [192]. A
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measure such as this would be obligatory for any neuropsychological study involving
DSM-IV bipolar patients, especially when being assessed during a period of clinical
remission. Unfortunately, at the beginning of this study it had been decided that
YMRS scores would not be collected as all of the patients tested had DSM-IV
recurrent MDD. However, with hindsight and given that 11 out of the 21 BSD
patients were subsequently found to have a past history of antidepressant-associated
hypomania, not including a measure of current manic symptoms in the test battery
was regrettable. None of the patients tested gave a history of recent hypomanic
symptoms or, on clinical assessment, appeared to have hypomanic symptoms during
testing. It is expected therefore that the effect of hypomanic symptoms at the time of
testing was not significant.
A related issue is the way in which control subjects were recruited. This was
done by asking patients enrolled in the study to volunteer a close friend, with no
history of depression, to take part. It may be that this method of recruitment
introduced a potential sampling bias in the sense that the controls may have been
more curious than the broader population to become involved in a study that involved
a psychiatric assessment and neuropsychological testing. In other words, the controls
may have been particularly interested in mental health issues or psychology with the
result that this could have biased some of their responses or made them more likely to
perform better on the neuropsychological tests than general population controls.
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b) What was the contribution ofcurrent medication to neuropsychological
performance?
As outlined in table 4, there may have been subtle differences between the BSD
patients and MDD patients in terms of medication at the time of testing (even though
a chi-squared analysis of classes of psychotropics was non-significant, table 3). In
general terms there were no large differences between the two groups in terms of
levels of antidepressant use but it must be acknowledged that one of the 42 MDD
patients was on no medication whereas all 21 of the BSD patients were on some kind
of psychotropic. Furthermore, 19% of the BSD patients were on combined therapy
(an antidepressant plus a mood stabiliser) compared to only 5% of the MDD patients.
Although the literature suggests that subtle cognitive impairments are most likely to
occur with traditional antipsychotic medications such as chlorpromazine,
benzodiazepines, lithium and anticholinergic antidepressants such as tricyclics |129,
146-148], the effect of combination therapy is unknown. It must be acknowledged
that some of the cognitive impairment observed in the BSD group may have been
caused by the higher rate of combination therapy in this group.
c) How significant was the difference in neurocognitive performance between BSD
patients, MDD patients and controls?
Several previous neuropsychological studies of mood-disordered patients have
detected subtle differences in cognitive performance between patients and controls
that do not necessarily extrapolate to functional impairments. The performance of
BSD and MDD patients in this study on many of the tests, by virtue of their high
premorbid levels of intellectual functioning, was relatively high and perhaps much
higher than would be expected for a population not selected from a University clinic.
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For this reason, it was important to calculate effect sizes for differences in
performance between the groups, as well as estimating how many of the BSD and
MDD patients fell below the 5th percentile of controls. The greatest effect sizes were
seen in the comparison of BSD patients with controls (which were generally in the
'large' range, defined as effect size greater than 0.8). Comparing BSD patients with
MDD patients produced effect sizes in the medium range (from 0.5 to 0.8) and
comparing MDD patients with controls produced both medium and low effect sizes
(less than 0.5).
Compared to other studies of this kind, these effect sizes are of a greater
magnitude that perhaps might have been expected. For example, in a comparison of
63 euthymic BPAD patients and controls, Thompson and colleagues calculated effect
sizes of 0.6 for the Stroop Colour Word Test, 0.6 for the RAVLT trials 1 to 5 total
free recall and 0.2 for the Trail-making test part B [134], The respective effect sizes
in the current study were 0.9 for the Stroop Colour Word, 1.0 for the CVLT trials 1 to
5 total free recall and 1.5 for the Trail-making test part B. Although there were
methodological differences between these two studies that may explain these
differences, the effect sizes reported in this thesis suggest that the differences found
between BSD patients and controls and BSD patients and MDD patients were
important.
This is supported by the calculations of how many BSD and MDD patients fell
below the 5lh percentile of controls (table 10). It is striking that 71% of BSD patients
were below the 5lh percentile of controls for the Trail-making test part A and that the
corresponding proportions for the Trail-making part B, Stroop Colour Word and
CVLT trials 1 to 5 total free recall were 52%, 48% and 38% respectively. For the
MDD patients, the corresponding figures were 45%, 21%, 29% and 17% respectively.
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d) How significant were the correlations between illness characteristics and
nenrocognitive performance ?
The calculation of correlations between age at onset and number of previous
depressive episodes with neurocognitive function in the MDD and BSD groups was
an exploratory exercise.
For both patient groups there were no significant correlations between number
of depressive episodes and any of the tests. However, in the MDD group, trails 1 to 5
total free recall and two of the five initial learning trials (trials 3 and 4) were
significantly negatively correlated with age at onset. Although this might suggest that
earlier age at onset of MDD is associated with greater impairment of verbal learning
and memory in the MDD group, the size of these correlations were relatively modest.
If the association between age at onset and verbal memory were more substantial it
might have been expected that several more of the CVLT categories would have been
significant. The same applies to the BSD group, where only two of the CYLT
categories (both in cued recall) were significantly negatively correlated with age at
onset. There was no correlation in either group between age at onset and
attention/executive performance.
To summarise these findings, it appears that overall there were no strong
correlations in either patient group between age at onset or number of previous
depressive episodes and neurocognitive performance. However, there were weak
negative correlations between age at onset and verbal memory performance in both
the BSD and MDD groups that were more pronounced in the MDD group. One
possible explanation for this might be that hippocampal function in both patient
groups is more strongly influenced by earlier onset of illness than the experience of
repeated episodes of depression. This might suggest that hippocampal function in
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these young patients is more closely related to higher genetic loading for mood
disorder (which might cause an earlier age at onset) rather then the neurotoxic effect
of repeated episodes. Although interesting, this is obviously a tentative suggestion
because the correlations observed were so weak. Furthermore, it might have been
expected that the BSD group correlations would be stronger than the MDD group
correlations because the former would have been expected to have a higher genetic
loading for mood disorder.
e) Can these findings be generalised to other populations?
As noted above, this sample of patients and controls were highly selected and may be
unrepresentative of the general population. All were recruited from a University
Health Service, most were either undergraduate or postgraduate students, the social
class distribution was relatively high and there were lower than expected rates of drug
and alcohol misuse. These represent limitations in terms of the degree to which the
findings of this study can be generalised to broader patient populations. This applies
particularly to the diagnostic findings. There have been reports that bipolar disorder
is associated with higher social class [193], greater social achievement in first degree
relatives [194] and greater premorbid educational achievement [195 ],
1 lowever, it might be argued that the homogeneity of the patient and control
samples represent a strength of the neuropsychological study in the sense that both
groups were young, they appeared to have low rates of substance misuse and, by
virtue of coming from families of higher social class, may have been more likely than
other samples to be free from major traumatic events in childhood (although this latter
point is presumed and was not formally assessed).
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f) Were the definitions of 'clinical remission' and 'euthymia' sufficiently rigorous?
It might be argued that a monthly clinical assessment of clinical remission and a
HRSD of less than 8 were inadequate to be clear about euthymia (even though this
definition is more stringent than that used in many previously published reports). It
has been suggested that serial, and if possible daily, objective and subjective
measurements of mood over at least a month and preferably over 3 months are
necessary to establish euthymia with a high degree of certainty [134, 196].
Although it is possible that some of the patients assessed in the current study
were not fully recovered for a sufficiently long time to be clear that they were
clinically euthymic, as noted above, an additional analysis that took into account
current HRSD scores was conducted (table 7). This did not influence the
neurocognitive findings or the levels of significance. Given also that the raw HRSD
scores for the three groups were not significantly different from each other, it is
reasonable to suggest that residual depressive symptoms in this data set did not
significantly confound the main findings.
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4.2.3 Future directions
it seems possible that one of the explanations for the large number of studies carried
out to date on the neuropsychology of mood disorders is the relative ease with which
these studies can be conducted (compared, for example, to structural or functional
imaging studies). On their own, neuropsychological studies are only able to point to
potential abnormalities within putative neural circuits of mood disorder. The
incorporation of structural and functional imaging data into studies of neurocognitive
function will be necessary to visualise abnormalities of these circuits.
From a review of the literature, it is clear there remains a need for carefully
designed studies that compare well matched samples of bipolar patients with unipolar
patients and controls. This kind of comparison may help to clarify whether the
neuropsychological profile of euthymic bipolar disorder is different from that of
euthymic recurrent unipolar depression. Ideally, such studies should be able to take
into account factors such as age at onset, number and severity of mood episodes,
family history for mood disorder, current mood symptoms and the effects of past and
current medications. In this regard, a prospective design (rather than a cross-sectional
comparison) would be preferred as this would be able to separate out the effects of
vulnerability from scarring and state effects.
One suggestion might be to recruit a cohort of medication-nai've adolescents
with major depression and carry out serial neuropsychological assessments over a
number of years (both during mood episodes and at times of rigorously-defined
remission). From what is known from previous long-term follow-up studies, a
proportion of these patients (perhaps up to 20%) would be expected to go on to
develop a bipolar disorder during an assessment period of 20 years. Comparison of
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bipolar patients and unipolar patients during this time period, taking into account the
effects of illness course and medication, may be useful in helping to define the
neuropsychological profile of bipolar disorder and recurrent unipolar depression.
Although an ambitious undertaking, the usefulness of this kind of study would
be greatly enhanced by incorporating the examination of genetic risk factors and
putative endophenotypic measures (such as HPA axis function or personality
dimensions). It is likely that there is a complex relationship between genetic risk,
neuroendocrine function, neurocognitive function, personality and the unipolar or
bipolar phenotype. It could be argued that neuropsychological studies of mood
disordered patients are only useful if the effects of genetic risk factors and
neuroendocrine function are part of the study design. For example, it is known that
abnormalities of some of the candidate genes for mood disorder, such as brain derived
neurotrophic factor (BDNF), have important effects on cognition in both patients with
mood disorder and controls [197-199], Although it can be seen that this field is likely
to progress by the integration of several different experimental approaches, it must be
acknowledged that the execution of these studies is likely to be expensive and
logistically difficult.
A key question for the future is whether bipolar patients are different from
unipolar patients in terms of abnormalities of neural circuitry (detected through
neuropsychological study and/or imaging), or whether bipolar illness is simply the
expression a more severe form of unipolar disorder that arises as a consequence of
higher genetic loading. This issue is important not only because of the implications
for classification and diagnosis but also because it is likely to impact on treatment
choices for patients presenting with recurrent episodes of depression. It remains to be
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seen over the next few years whether the concept of a broadened bipolar spectrum
more widely accepted in clinical practice.
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• I understand that my general practitioner will be informed of my participation
in the study. I give my permission for my medical notes to be looked at and
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Blackwood and Dr Muir's team.
♦ I understand that I have the right to withdraw from the study without giving a
reason and without my medical treatment or legal rights being affected. I
understand that the results of these investigations are unlikely to have any
implications for me personally.
♦ I understand that I am under no obligation to take part in this study and a
decision not to participate will not alter the treatment I receive. I know how to
contact the research team if I need to.
Name of subject (block letters) Date Signature
Name of person taking consent Date Signature
Assessment instruments used in this study
Drug Use Questionnaire (DAST-20) (Skinner 1982)
The following questions concern information about your potential involvement with
drugs, not including alcohol, over the last 12 months. Please answer 'yes' or 'no' to
each of the following questions.
1. Have you used drugs other than those used for medical reasons?
2. Have you abused prescription drugs?
3. Do you abuse more than one drug at a time?
4. Can you get through the week without using drugs?
5. Are you always able to stop using drugs when you want to?
6. Have you had 'blackouts' or 'flashbacks' as a result of drug use?
7. Do you feel bad or guilty about your drug use?
8. Does your spouse or parents ever complain about your
involvement with drugs?
9. Has drug abuse created problems for you with your spouse or
parents?
10. Have you lost friends because of your use of drugs?
11. Have you neglected your family because of your use of drugs?
12. Have you been in trouble at work because of your use of drugs?
13. Have you lost a job because of drug use?
14. Have you been involved in fights when under the influence of
drugs?
15. Have you engaged in illegal activities in order to obtain drugs?
16. Have you been arrested for possession of illegal drugs?
17. Have you ever experience withdrawal symptoms when you
stopped taking drugs?
18. Have you had medical problems as a result of your drug use?
19. Have you gone to anyone for help with a drug problem?
20. Have you been involved in a treatment programme specifically
related to drugs?
Extra question: If you have ever smoked cannabis, would you say that
over the last year you have been smoking it on at least a
weekly basis?
Alcohol Use Disorders Identification Test (AUDIT) (Saunders 1993)
I am going to ask you some questions about your use of alcohol during the past year.
How often do you have a drink containing alcohol?
Never 0
Less than monthly 1
2 to 3 times a month 2
2 to 3 times a week 3
4 or more times a week 4
How many alcoholic drinks do you have on a typical drinking day?
None 0
1 or 2 1
3 or 4 2
5 or 6 3
7 or 9 4
10 or more 5
How often do you have six or more drinks on one occasion?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
How often during the last year have you found that you were unable to stop
drinking once you had started?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
How often during the last year have you failed to do what was normally
expected of you because of drinking?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
How often during the last year have you needed a drink first thing in the
morning to get yourself going after a heavy drinking session?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
How often during the last year have you had a feeling of guilt or remorse
after drinking?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
How often during the last year have you been unable to remember what
happened the night before because you were drinking?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
Have you or someone else been injured as a result of your drinking?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
Has a relative, friend, doctor or other health worker been concerned about
your drinking or suggested you cut down?
Never 0
Less than monthly 1
Monthly 2
Weekly 3
Daily or almost daily 4
(to be administered by a health care professional)
Patient's Name
Date of Assessment
To rate the severity of depression in patients who are already diagnosed as depressed, administer this
questionnaire. The higher the score, the more severe the depression.
For each item, write the correct number on the line next to the item. (Only one response per item)
I. DEPRESSED MOOD (Sadness, hopeless, helpless, worthless)
0= Absent
1= These feeling states indicated only on questioning
2= These feeling states spontaneously reported verbally
3= Communicates feeling states non-verbally—i.e., through facial expression, posture,
voice, and tendency to weep
4= Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non¬
verbal communication
2. FEELINGS OF GUILT
0= Absent
I = Self reproach, feels he has let people down
2= Ideas of guilt or rumination over past errors or sinful deeds
3= Present illness is a punishment. Delusions of guilt





1= Feels life is not worth living
2= Wishes he were dead or any thoughts of possible death to self
3= Suicidal ideas or gesture
4= Attempts at suicide (any serious attempt rates 4)
4. INSOMNIA EARLY
0= No difficulty falling asleep
1= Complains of occasional difficulty falling asleep—i.e., more than 1/2 hour
2= Complains of nightly difficulty falling asleep
5. INSOMNIA MIDDLE
0= No difficulty
1= Patient complains of being restless and disturbed during the night
2= Waking during the night—any getting out of bed rates 2 (except for purposes of voiding)
Adapted from Hedlung and Viewcg. The Hamilton rating scale for depression. Journal of Operational Psychiatry, I 979; 10(2): 149-1 65.
INSOMNIA LATE
0= No difficulty
1= Waking In early hours of the morning but goes back to sleep
2= Unable to fall asleep again if he gets out of bed
WORK AND ACTIVITIES
r. .0= Noxiifficulty
1= Thoughts and feelings of incapacity, fatigue or weakness related to activities; work <
hobbies
2= Loss of interest in activity; hobbies or work—either directly reported by patient, or
indirect in listlessness, indecision and vacillation (feels he has to push self to work (
activities)
3= Decrease in actual time spent in activities or decrease in productivity
4= Stopped working because of present illness
RETARDATION: PSYCHOMOTOR (Slowness of thought and speech; impaired ability
to concentrate; decreased motor activity)
0= Normal speech and thought
1= Slight retardation at interview






2= Playing with hands, hair, etc.
3= Moving about, can't sit still
4= Hand wringing, nail biting, hair-pulling, biting of lips
ANXIETY (PSYCHOLOGICAL)
0= No difficulty
1= Subjective tension and irritability
2= Worrying about minor matters
3= Apprehensive attitude apparent in face or speech
4= Fears expressed without questioning
ANXIETY SOMATIC: Physiological concomitants of anxiety; (i.e., effects of autonomic
overactivity, "butterflies," indigestion, stomach cramps, belching, diarrhea, palpitations,
hyperventilation, paresthesia, sweating, flushing, tremor, heacfecKe,' uffrtary frequency).






12. SOMATIC SYMPTOMS (GASTROINTESTINAL)
0= None
1= Loss of appetite but eating without encouragement from others. Food intake
about normal
2= Difficulty eating without urging from others. Marked reduction of appetite and
food intake
13. SOMATIC SYMPTOMS GENERAL
0= None
1= Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy
and fatigability
2= Any clear-cut symptom rates 2








2= Preoccupation with health
3= Frequent complaints, requests for help, etc.
4= Hypochondriacal delusions
16. LOSS OF WEIGHT
A. When rating by history:
0= No weight loss
1= Probably weight loss associated with present illness
2= Definite (according to patient) weight loss
3= Not assessed
17. INSIGHT
0= Acknowledges being depressed and ill
1= Acknowledges Illness but attributes cause to bad food, climate, overwork, virus, need
for rest, etc.
2= Denies being ill at all
18. DIURNAL VARIATION
A. Note whether symptoms are worse in morning or evening. If NO diurnal variation, mark none
0= No variation
1= Worse in A.M.
2= Worse in P.M.















2= Ideas of reference
3= Delusions of reference and persecution
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Clinical Global Impression of Illness Scale (Guy, 1976)
Severity of Illness (CGII)






Among most extremely ill 7
Clinical Global Impression (CGIC)






Very much worse 7





















Person being described ID:
Month
Is person being described living?
Age and Year when last seen or known about, or died:





































1 .b) Age of onset
Episodes
1 .c) Number of episodes
Weeks
1 .d) Duration of longest episode in weeks
Code
Response
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FIGS: GENERAL SCREENING QUESTIONS Page 1
Interview date: — —
Month Day Year
Use One Per Informant





INTERVIEWER: Before you begin, you need to generate or obtain a pedigree on which to record all of the
responses to the following General Screening Questions. (See FIGS Manual for details.)
Step 1: Let's go over yourfamily tree. (Include spouse and his/her parents and siblings, offspring, parents,
siblings, aunts, uncles, cousins, grandparents, as well as any other relatives the informant can recall.)
Step 2: Now I am asking you to keep in mind all those in yourfamily tree as I go through this list of
questions. (Note all positive responses on the pedigree.)
Was anyone adopted?
Was anyone mentally retarded?
Did anyone:
Have problems with their nerves or emotions? Take medicine or see a doctorfor it? Take
lithium?
Feel very lowfor a couple of weeks or more, or have a diagnosis ofdepression?
Attempt or complete suicide?
Seem overexcited (or manic) day and night, or have a diagnosis ofmania?
Have visions, hear voices, or have beliefs that seem strange or unreal?
Have unusual or bizarre behavior, or have a diagnosis ofschizophrenia?
Page 2 FIGS: GENERAL SCREENING QUESTIONS
FIGS
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Have trouble with the police, with completing school, or with keeping a job?
Have alcohol or drug use that causedproblems (with health, family, job, or police)? Go to
AA or NA, or have treatment for this?
(Was anyone) hospitalizedforpsychiatric problems, orfor drug or alcohol problems?
Have inherited medical diseases such as Huntington's disease or seizure disorder or any
other disorders of the brain or nervous system?
(Did anyone) have fewfriends, or seem to be a loner?
(Did anyone) seem odd or eccentric in behavior or appearance?
(Was anyone) extremely jealous, or suspicious, or believe in magic, or see special meanings
in things that no one else saw?
Step 3: Complete a Face Sheet for each of the informant's first degree relatives and spouse. If he/she knows
well other affected relatives, also complete a Face Sheet for them. In addition, for each of these given
a positive response in the General Screening, complete the symptom checklist for any suspected:
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Code for a single episode (best recalled, worst episode if possible).
1. During depression...
1 .f) ...did he/she move or speak more slowly than usual?
1 .g) ... did he/she pace or wring his/her hands?
... did he/she have less energy or feel tired out?
...did he/she feel guilty, worthless or blame himself/herself?
...did he/she have trouble concentrating or making decisions?
l.k) ...did he/she talk ofdeath or suicide? Or try suicide?
1.1) .. .did he/she have visions, or hear voices, or have beliefs or behavior that seem
strange or unusual, at the same time as (symptoms above)? (If YES, complete
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3.








4. Number of episodes
5. Duration of longest episode in weeks
6. Rate and code impairment or incapacitation:
0. None
1. Modified RDC Impairment
2. Modified RDC Incapacitation
3. RDC Minor Role Dysfunction
4. Change from previous functioning
9. Unknown


























Interview date: — —
Month Day Year
Family last name: Family ID Number:
No Yes Unk
1. For most ofthe time day and night over several days, did he/she (more than usual).
•f) ...behave in such a way as to cause difficultyfor those around him/her
(obnoxious/manipulative) ?
1 .g) .. feel that he/she had special gifts or powers?
1 .h) ... become more talkative than usual?
l.i) ...jumpfrom one idea to another?
1 .j) ... become easily distracted?
1 .k) .. .get involved in too many activities at work or school?
1.1) ...have visions? hear voices? have beliefs or behavior that seem strange or
unusual? at the same time as (above symptoms)? (If YES, complete a
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3. Age of onset
4. Number of episodes
5. Duration of longest episode in weeks
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Interview date: — —
Month Day Year













Code for a single episode (best recalled, worst episode if possible).
No Yes Unk
Because ofdrinking, did he/she ever have problems such as...
l.a) ...being unable to stop or cut down on drinking? 0 1 9
Lb) ...spending a lot of time drinking or being hung over? 0 1 9
l.c) ...being unable to work, go to school, or take care ofhousehold 0 1 9
responsibilities ?
l.d) ... being high from drinking when he/she could get hurt? 0 1 9
l.e) ... accidental injuries? 0 1 9
1-0 . ..reducing or giving up important activities? 0 1 9
1-g) . ..objectionsfrom the family orfriends, at work or school? 0 1 9
Lh) ...legalproblems more than once (DWIs, arrests)? 0 1 9
1-i) ... blackouts more than once? 0 1 9
1-j) ...binges or benders more than once? 0 1 9
l.k) ...physical health problems (liver disease, pancreatitis)? 0 1 9
1.1) ...emotional orpsychological problems (uninterested, depressed, 0 1 9
suspicious/paranoid, having strange ideas)?
l.m) ...withdrawal symptoms (shakes, seizures/convulsions, DTs)? 0 1 9
Code Response





3. AA or other self-help:
4. Medication:
9. Unknown
Describe details and/or other treatment:
3. Does he/she currently have a problem with alcohol?
No Yes Unk
0 1 9
'age 2 FIGS: ALCOHOL & DRUG ABUSE CHECKLIST FIGS
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1. Record age he/she began to have alcohol-related problems.
5. Record age he/she stopped drinking heavily.
DRUG ABUSE/DEPENDENCE




Because ofhis/her drug use, did he/she have...
7.a) ... physical health problems (hepatitis, overdose, withdrawal symptoms,
accidental injuries)?
7.b) ... emotional or psychological problems (uninterested, depressed,
suspicious/paranoid, having strange ideas)?
7.c) ... legal problems (arrests for possessing, selling, or stealing drugs)?
7 .d) ... problems with family or friends ?
7.e) ... troubles at work or school?





3. NA or other self-help:
4. Medication:
9. Unknown











0 1 2 3 4 9
9. Does he/she currently have a problem with drugs?
10. Record age he/she began to have drug-related problems.

























Interview date: — —
Month Day Year
Family last name: Family ID Number:
PSYCHOSIS
Code for a single episode (best recalled, worst episode if possible).
1. What were his/her unusual beliefs or experiences?
Specify:
Did he/she ever...
1 .a) ... believe people were following him/her, or that someone was trying to hurt or
poison him/her?
1 .b) ... believe someone was reading his/her mind?
1 .c) ... believe he/she was under the control ofsome outside person orpower or
force?
1 .d) ... believe his/her thoughts were broadcast, or that an outside force took away
his/her thoughts orput thoughts into his/her head?
1 ,e) ... have any other strange or unusual beliefs?
If yes: Describe:
No Yes Unk
1 .f) .. .see things that were not really there?
Page 2 FIGS: PSYCHOSIS CHECKLIST FIGS
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No Yes Unk
l.g.l) (Code YES if: voice with content having no relation to depression or 0 1 9
elation, or voice keeping up running commentary on subject's behavior
or thoughts, or two or more voices conversing.)
1 .h) . ..speak in a way that was difficult to make sense of.? 0 19
If yes: Describe:
l.i) ...seem to be physically stuck in one position, or move around excitedly without 0 19
any purpose?
l.j) ...appear to have no emotions, or inappropriate emotions? 0 19
Weeks
2. How long did the longest of these experiences last?
INTERVIEWER: If less than 1 week (unless successfully treated), STOP
HERE. Otherwise continue, if informant is knowledgeable
about this person.
<
INTERVIEWER: If subject did NOT have any episode of Major Depression or Mania (by FIGS
checklists from this informant), skip to question 6.
No Yes Unk
1 9
INTERVIEWER: For the rest of this checklist, "illness duration" refers to total time of illness, including




(Probe and code YES if mania and/or depression lasted at least 30% of total duration 0




5.a) (Code YES if the above was true for as long as two weeks.) 0 1 9
FIGS
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Code Response







Describe details and/or other treatment:
7. Age of onset
8. Number of episodes (Code 001 if chronic symptoms and/or treatment since onset)
9. Total illness duration (all episodes, includes active and prodromal
and/or residual symptoms and/or treatment.
















INTERVIEWER: If informant apparently does not know subject well enough to give information on
Prodromal/Residual symptoms, STOP HERE.
If duration criterion for DSM I1I-R Schizophrenia, Chronic Type, already met,
(question 9, total illness duration > 2 years), STOP HERE.
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INTERVIEWER: Use this page only if Schizo-affective is ruled out (by questions 3 to 5 above), or if the
psychosis symptoms lasted at least one week (or shorter duration if successfully treated).
Establishing the Prodromal Period:
16. Now I would like to ask you about the year
before his/her (psychotic symptoms)
started. During that time did he/she...
(Ask after completing question 16.a-n for the Prodromal period:)
Establishing the Residual Period:
Now I would like to ask you about the year after his/her







16.a) .. .stay away from family andfriends, become socially isolated? 0 1 9 0 1 9
16.b) .. .have trouble doing his/herjob, going to school, or doing
work at home?
0 1 9 0 1 9
16.c) .. .do something peculiar like talking to self in public? 0 1 9 0 1 9
16.d) .. .neglect hygiene and grooming? 0 1 9 0 1 9
16.e) .. .appear to have no emotions or inappropriate emotions? 0 1 9 0 1 9
16.f) .. .speak in a way that was hard to understand, or was he/she at
a loss for words?
0 1 9 0 1 9
16.g) .. .have unusual beliefs or ideas? 0 1 9 0 1 9
16.h) .. .have unusual perceptions, like sensing the presence ofa
person not actually present?
0 1 9 0 1 9
16.i) .. .have no interests, no energy? 0 1 9 0 1 9
16.j) .. find special meaning in TV, radio, or newspaper articles? 0 1 9 0 1 9
16.k) ...feel nervous with other people? 0 1 9 0 1 9
16.1) .. .worty that people were out to get him/her? 0 1
Weeks
9 0 1 9
17.a) How long did he/she have these experiences?
INTERVIEWER: Return to top of question 16 to establish the Residual period and code
in Residual Column.
Weeks
17.b) How long did he/she have these experiences after his/her
(Active psychotic features) stopped?
No Yes Unk

























Code for a single episode (best recalled, worst episode if possible).
1. Does he/she...
1 .a) ...often keep an eye out to stop people from taking advantage ofhim/her?
Expects, without sufficient basis, to be exploited/harmed by others.
1 .b) .. .get concerned that friends or co-workers are not really loyal or trustworthy?
Questions, without justification, loyalty of friends or associates.
1 .c) . ..often pick up hidden threats orput-downs from what people say or do?
Reads hidden demeaning or threatening meanings into benign remarks or
events.
1 -d) ... take a long time to forgive someone ifthey have insulted or hurt him/her?
Bears grudges or unforgiving of insults/slights.
1 .e) . ..seem to believe it is best not to let other people know much about him/her?
Reluctant to confide in others because of unwarranted fear that information will
be used against him/her.
1 .f) . ..often get angry about being insulted or slighted?
Easily slighted, quick to react with anger or counterattack.
1 .g) .. .seem to be a jealous person? Ever suspected that his/her spouse/partner was
unfaithful?
Questions, without justification, fidelity of spouse or sexual partner.
SCHIZOID PERSONALITY
2. Does he/she...
2.a) ...seem not to want or enjoy close relationships, like with family orfriends?
Neither desires nor enjoys close relationships, including family.
2.b) ...prefer to do things alone rather than with other people?
Almost always chooses solitary activities.
2.c) ... hardly ever seem to have strong feelings, like being very angry or very
happy?
Rarely, if ever, claims or appears to experience strong emotions, anger/joy.
2.d) ...seem uninterested in being sexually involved with another person?





























2.e) ...seem not to care ifpeople praise or criticize him/her? 0 19
Indifferent to praise and criticism from others.
2.f) ...have no one to be really close to or confide in, or just one person, outside of 0 19
the immediate family?
No close friends or confidants, or only one, other than first-degree relatives.
2.g) ...act cold or distant, hardly ever smile or nod back at people? 0 19
Constricted affect, aloof, cold, rarely reciprocates gestures or expressions.
SCHIZOTYPAL PERSONALITY
3. Does he/she...
3 .a) ... wonder ifpeople talking to each other are talking about him/her? Say that a 0 1
common event or object is a special sign for him/her?
Ideas of reference (not delusions of reference).
3.b) ...often act nervous in a group ofunfamiliarpeople? 0 1
Excessive social anxiety.
3.c) ...reports experiences with the supernatural? Believe in astrology, seeing the 0 1
future, UFOs, ESP or a "sixth sense "?
Odd beliefs or magical thinking, influencing behavior and inconsistent with
subcultural norms.
3.d) ...mistake objects or shadowsfor people, or noisesfor voices? Have a sense 0 1
that some invisible person orforce is around? See faces change before his/her
eyes?
Unusual perceptual experiences.
3.e) .. .behave in odd or eccentric ways? Look peculiar or untidy, have unusual 0 1
mannerisms, talk to him/herself?
Odd, eccentric, peculiar behavior or appearance.
3.f) ...sometimes make it hard to follow what he/she is saying? Ramble off the 0 1
subject, talk in vague or abstract terms?
Odd speech (without loosened associations or incoherence).
3.g) ...sometimes act silly, not in keeping with the situation? Or tend not to show any 0 1
feelings in response to people?
Inappropriate or constricted affect (e.g., silly or aloof).
INTERVIEWER: If any YES to any Personality Disorders, ask the following questions (to be used for
research, not diagnosis).
IMPAIRMENT/DISTRESS
4. Does he/she have problems because ofthis behavior or thinking orfeeling—either
with the family or socially, or at work or school? 0 19
Significant social or occupational impairment.
5. Does this behavior or thinking orfeeling cause the person unhappiness?
Significant subjective distress. 0 1 9
Code Response







Please indicate which hand you prefer to use for the following activities by putting a
tick in the appropriate column.
RR You would always use your right hand
R You prefer using your right hand
E You have no particular preference for either hand
L You prefer using your left hand
LL You would always use your left hand
Please try to act each task through before answering and do not assume that the same
hand will be preferred throughout.
LL L E R RR
1. Throwing a dart
2. Using an electric iron
3. Painting a picture
4. Using a toothbrush
5. Using a table-tennis bat
6. Pushing in a drawing pin
7. Polishing shoes ^ l
8. Throwing a ball
9. Rubbing something out
10. Combing your hair ,-v 'J.
11. Slicing bread
12. Using a corkscrew y ■ «
13. Striking a match




. •* ?: vsor'1
Q- As far as you are aware, are you colour-blind? Y N
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i-kwiv'a-kl IDYLL id'il, id'al '
na-ev PUERPERAL pu-ur'par-al
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31 | 92 92 i 94 I
; 122 119 120 32 91 91 93
: 121 118 119 33 90 90 91
j 120 117 118 !1
1
34 j 89 89 90
118 116 117 ! 35 j 87 87 89
117 115 116 36 ! 86 86
1 •
; 88 i
116 114 115 37
I 85 85 87
115 113 114 38 • 84 84 85
i






112 .110 in ! ^0 « 81 82 84





42 79 80 82
, 108 107 108 43 i 77 78 80 !
j 107 106 107 44








105. 103 105 46 74 75 77'
: 103 102 104 47 i 73 74 76, It ' i
102 101 102
. 48 71 73 : . ts. i
i 101
j










70 ! 73 !
! i
ig these tables,
SE est of Full Scale IQ = 8.6
SE est of Verbal IQ = 7.3
SE est of Performance IQ = 11.5
5 BLCM DESIGN Discontinue after 3 consecutive failures.







CT> O 16-60 11-15 1-10
0 4 5 6
60" 16-60 11-15 1-10
0 4 5 6
bCO 21-60 16-20 11-15 1-10
0 4 5 6 7
120" 36-120 26-35 21-25 1-20
0 4 5 6 7
120" 61-120 46-60 31-45 1-30
0 4 5 6 7
120" 76-120 56-75 41-55 1-40
0 4 5 6 7
120" : 76-120 56-75 41-55 1-40









































































































































































































































































































































The Brixton Spatial Anticipation Test
'There arc many pages here which all have the same basic design on
them. There arc alwaysten 'positions; and one ofihem is always
coloured blue' [point to filled circle on page brie].' f.However the
coloured one moves around according to various patterns'that come
and go without warning. These nffmbers '[pSifit to numbers '
underneath the circles] arc just here to refer to the position - there . ■
is nothing complicated or.mathematical about this test'.
'Now, asl turn the pages over, your job is to pick up oil the pattern
as best you can, and point to where you think the blue one is going to
be on the next page. It's not guess-work - you can work it out. For
instance, imagine the blue one was here[point to position 6], ami
: then when] turn the page it goes toy, and then to 8, then top -you ,
might reasonably expect it next to go to To'.
'From time to. time the'pattern.changes.without warning, and then
it is your job to pick up on the hew pattern .as best you can. Do you
understand?'
Give further assistance if necessary'
'Obviously the first time youhavc nothing to'go on,so your first
answer will have to be a guess - have'a guess as to where the blue one;.
'
will be next' '
Item/ Correct Subject's
page answer response
29* .. 8 T.'
• 30 . i
31 2 ■
■' 32 ? ... 3 i
















' 45 : 9
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0-/ 10 Very superior
8 ; 9 Superior
9-10 8 Good
11 13 7 I ligl i averaye
14—17 6 Average
18-20 5 Moderate ave.
21-23
, 4 Low average
24-25 3 Poor
26-31 2i Abnormal .
>31 1 Impaired •
Scaled score








Form C Stimulus Sheet
BLUE RED TAN RED
GREEN GREEN RED TAN
TAN TAN TAN REDS.
RED BLUE BLUE TAN
GREEN • GREEN
, TAN BLUE
BLUE BLUE RED GREEN
GREEN
. TAN GREEN RED
BLUE
. GREEN RED BLUE
RED TAN - BLUE RED
BLUE
. BLUE TAN TAN
TAN GREEN RED GREEN
RED BLUE GREEN TAN
TAN GREEN RED BLUE
GREEN RED TAN RED
BLUE BLUE BLUE BLUE
TAN GREEN TAN RED
GREEN TAN GREEN GREEN
RED RED TAN RED
TAN TAN BLUE BLUE
RED GREEN TAN TAN
TAN TAN BLUE BLUE
RED RED GREEN GREEN
GREEN BLUE RED BLUE
RED RED GREEN RED
TAN GREEN TAN BLUE
BLUE RED RED TAN
GREEN - TAN GREEN BLUE
TAN BLUE BLUE GREEN
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